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Chapter 1. Introduction 
A. Background and significance  
Colorectal cancer (CRC) is the third most common incident cancer and the fifth leading 
cancer killer in 2012 in the world 1. In the Unites States (U.S.), the estimated age-
standardized rate (ASR) of CRC incidence is more than twice of that in the world (42.4 
per 100,000 based on data from 2008-2012 vs 17.2 per 100,000 for both sexes) 1,2, 
despite the slightly decreasing trend over time 3. Therefore, understanding the etiology 
of CRC and developing effective preventive strategies are still the most attractive public 
health goals. 
 
CRC arises from the malignant transformation of adenomas and polyps 4. The 
development of CRC is complex and multi-factorial. Both external factors and/or 
inherited genetic factors play an essential role in the initiation and progression of the 
adenoma-carcinoma sequence 5. Epidemiological studies have reported inverse 6–14 as 
well as null associations 15,16 between calcium intake and the risk of colorectal neoplasia. 
Although inconsistent, calcium, one of nutrients with chemopreventive effects, was 
found to reduce 20-30% of risk for colorectal adenoma 17–20 and cancer 21,22. Clinical 
trials also found that calcium supplementation reduced about 20% risk of  
metachronous colorectal adenoma 23–25. In addition, recent studies indicate that calcium: 
magnesium (Ca:Mg) intake ratio modified the associations between intakes of calcium 
and magnesium and risk of gastrointestinal neoplasia 17,26,27, and total, cardiovascular 
disease and cancer mortalities 28. These studies also indicated that a ratio between 1.7 
and 2.6 is needed for calcium intake to be protective against risk of colorectal neoplasia, 
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and total, cardiovascular disease and cancer mortalities 17,26–28. It is possible that lack of 
consideration in Ca:Mg balance may explain some of the inconsistency in previous 
studies on calcium intake.  
 
The removal of polyps within an endoscopy screening is the most effective prevention 
strategy to reduce the morbidity and mortality of CRC 29. However, recent evidence 
suggested that colonoscopy is more related to the reduction of left-side colon deaths, 
but not right-side 30–32. Furthermore, annual recurrence rates in patients with small and 
advanced adenomas were as high as 19.3% and 22.9%, respectively 33. Therefore, 
additional preventive strategies are necessary.  
 
Studies have shown that individuals with type 2 diabetes 34–37 and metabolic syndrome 
38–40 have an elevated risk of CRC . Magnesium deficiency is a contributor to age-
related diseases including cancer and cardiovascular disease. 41–44. Calcium and 
magnesium may share the same homeostatic regulation system 45 primarily through 
absorption in the intestine and reabsorption in the kidneys to maintain the balance of 
Ca:Mg 45,46.  Nevertheless, calcium and magnesium compete with each other in 
(re)absorption and transport 47–51. Experimental evidence in animals showed that 
calcium-adequate and magnesium-deficient diets may increase heart lipid peroxidation, 
plasma levels of triglycerides, and inflammatory markers; whereas both calcium-
deficient and magnesium-deficient diets were associated with significant reductions in 
inflammatory markers, lipid peroxidation and a normal plasma triglyceride level 52,53. 
However, no previous human study has examined the potential modifying effect of the 
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Ca:Mg intake ratio in relation to the lipid panel and uric acid, which may have a role in 
the development of colorectal neoplasia. This is supported by findings from recent 
studies which indicated that Ca:Mg intake ratio modified the associations between 
intakes of calcium and magnesium and risk of total, cardiovascular disease and cancer 
mortalities 28. 
 
B. Study objectives  
This thesis is composed of three projects and has three well-connected purposes:  
Project A. Calcium: magnesium intake ratio and colorectal carcinogenesis, results from 
the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. 
1A. To determine the modifying effect of Ca:Mg intake ratio on the association between 
calcium intake and the risk of colorectal neoplasia. 
1B. To measure the association between calcium intake and risks of incident adenoma, 
metachronous adenoma, and CRC. 
1C. To assess whether calcium intake provides additional protection against incident 
colorectal neoplasia in individuals receiving endoscopic screenings 
 
Project B. Ca:Mg Ratio and Lipid Profile, a Randomized Clinical Trial. 
1A. To examine the effect of magnesium supplementation may have in the change of 
lipid biomarkers in the Personalized Prevention of CRC Trial (PPCCT)  
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1B. To investigate whether reducing the Ca:Mg intake ratio under 2.6 among 
participants with high ratios by magnesium supplementation changes the serum lipid 
level in the PPCCT. 
 
Project C. Ca:Mg Ratio and Uric acid, a Randomized Clinical Trial. 
1A. To examine whether the magnesium supplementation may have a role in uric acid 
metabolism  
1B. To investigate whether reducing the Ca:Mg intake ratio under 2.6 among 
participants with high ratios by magnesium supplementation changes the serum uric 
acid level in the PPCCT 
 
C. Organization of the thesis  
This thesis is divided into five chapters. Chapter 1 is an overall introduction of the 
studies including the introduction of background and significance of the studies, the 
objectives of the thesis and the structure of the thesis. Chapter 2 reviews the topic of 
main exposures as well as outcomes in details. Chapter 3 presents the research 
methods applied in studies including descriptions of populations, the data collection, 
power analyses, and the statistical analysis. Chapter 4 is a result section. Chapter 5 
discusses and summaries key findings, significance and implications of the study results. 
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Chapter 2. Literature review 
A. Colorectal neoplasia 
1. The worldwide and United States burden 
CRC is the third most common incident cancer with an estimated worldwide age-
standardized rate (ASR) of 17.2 per 100,000 for both sexes in 2012 1. Men usually have 
slightly higher incidence rates than women (overall sex ratio 1.44:1) 1. Based on cancer 
statistics from the Surveillance, Epidemiology, and End results program, CRC incidence 
rates have great geographical variations 54. The majority (55%) of the cases occur in 
more developed regions 54. Australia/New Zealand has the highest estimated incidence 
rates with ASRs of 44.8 and 32.2 per 100,000 in men and women, respectively. On the 
other hand, the lowest incidence occurs in Western Africa (ASR: 4.5 and 3.8 per 
100,000 for men and women respectively) 54. However, global trends are changing over 
time: certain countries such as Japan and Korea with historically low incidence are 
currently increasing; while historically high-risk countries are variably increasing 
(Finland, Norway), remaining steady (in most Western and Northern European countries) 
or decreasing (the U.S.) 3.  
 
The worldwide estimated age-standardized mortality rate is 8.5 per 100,000 for both 
sexes in 2012, which ranked CRC as the fifth leading cancer related death in the world 1. 
There is less geographical variation in mortality rates; however, more deaths (52%) 
happen in the less developed regions of the world 54. The estimated mortality rates are 
the highest in Central and Eastern Europe (ASR: 20.3 per 100,000 for men, 11.7 per 
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100,000 for women), and the lowest in Western Africa (ASR: 3.5 and 3.0 for men and 
women per 100,000, respectively) 54.  
 
CRC is the third most common incident cancer in the U.S. 55, with an incidence rate of 
43.7 per 100,000 men and women per year based on 2007-2011 statistics 56. CRC is 
also the third leading cause of cancer-related death 55 with 15.9 deaths per 100,000 for 
both sexes per year 56. It appears that there is an average 3% reduction per year for 
CRC incidence (Figure 2.1) and mortality (Figure 2.2) rates from the years 2002 to 
2011 57.   
 
CRC incidence and mortality rates vary widely by race and ethnicity within the U.S. 55. 
Generally, both incidence and mortality rates are highest in blacks and lowest in 
Asians/Pacific Islanders. Based on data from 2006 to 2010, incidence rates in blacks 
are nearly 50% higher than those in Asians/Pacific Islanders; death rates in blacks (29.4 
per 100,000 population) are almost twice as high as those in Asians/Pacific Islanders 
(13.1) 55. 
 
The stage of CRC is determined by “size and extent of the primary tumor, absence or 
presence of regional lymph node involvement, and absence or presence of distant 
metastases” 58. The stage of cancer at diagnosis is essential in determining the type of 
therapy and estimating prognosis outcome 3. The earlier CRC is discovered and treated, 
the better survival rates appear. The five-year survival rates are 90.3%, 70.4% and 12.5% 
for local, regional and distant stages, respectively 55. Forty percent of patients with CRC  
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Figure 2.1 The age-standardized CRC incidence rate by ethnicities in the U.S. 
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Figure 2.2 The age-standardized CRC mortality rate by ethnicities in the U.S.
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are diagnosed with localized disease and 36% and 20% of CRC s are diagnosed with 
regional and distant disease, respectively 55. In an early stage, CRC is usually 
asymptomatic while symptoms such as a change in bowel habits, rectal bleeding, and 
blood in stool may appear in a later stage 3. Both the absence of symptoms until later 
stages and the availability/use of screening affect the stage of diagnosis.  
 
CRC is most commonly diagnosed in the proximal colon (42%) followed by the rectum 
(28%) and distal colon (23%) 55. The etiologies and carcinogenesis of CRC varies 
substantially by site of diagnosis 55,59–61. The frequency of CRC by subsites varies with 
age and sex. In the population with age over 65 years, women have higher rates of 
CRC incidence and mortality, compared with men 62. Women, especially aged 80 years 
and older, have a higher proportion of proximal colon cancer, while men are more likely 
to be at risk of rectal cancer 63–65. It was hypothesized that oral contraceptive and 
hormone related-factors may explain potential differences in CRC risk by subsite and 
sex 63,66. However, the mechanism of sex differences in subsite-specific CRC has not 
been fully understood.  
 
2. The development of colorectal neoplasia 
2.1 Anatomic features and physical function of the colon and rectum  
An integral part of the digestive system, the colon is the first part of the large bowel, is  
connected to the small bowel at the lower right abdomen and is about 5 feet long 67. The 
four sections of the colon include ascending, transverse, descending, and sigmoid 
regions. The colon absorbs mineral nutrients and water from the food passed through 
10 
 
this tube, and retains the waste matter which is eventually expelled it through the 
rectum and anus, which is the end of the large intestine that is about 6-8 inches long 67.   
 
The wall of colon and rectum is made up of several layers. From the inner to the outer,  
its layers include mucosa, submucosa, thick muscle layers, subserosa and serosa (only 
for colon but not for rectum) 68. The mucosa is the inner lining of colon and rectum and 
contains three layers (epithelium, connective tissue, and thin muscle layer). The 
submucosa is a layer of fibrous tissue under the mucosa 68. A thick muscle layer 
beneath submucosa is vital in expelling fecal matter 68.    
 
2.2 The natural history of adenoma-carcinoma sequence 
A polyp is a small cluster of nonmalignant cells and can form in the lining of colon or 
rectum 69. Adenomas and hyperplastic polyps are two broad types of polyps that may 
develop. The colorectal adenoma is a benign glandular tumor of the colon and rectum 
70,71. Previous studies have identified the potential precursor role of adenomas in CRC 
development, thus a hypothesis of adenoma to carcinoma sequence was first reported 
in 1951 72. Although it is still debatable, geographical, pathological as well as 
epidemiological evidence indicate the possibility of the adenoma-carcinoma sequence. 
The adenoma prevalence in geographical areas was correlated with CRC incidence in 
those same regions 73. The evidence of reduction in CRC incidence after endoscopic 
removal of adenomas supports the theory of the adenoma-cancer sequence because 
removal of adenomas by polypectomy has been shown to reduce the incidence and 
mortality of CRC 74,75. Moreover, colorectal carcinomas were observed to arise at the 
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site of polyps left in situ and 70. In addition, there is evidence of a temporal relationship 
between adenoma and CRC development: the average age of diagnosis with an 
adenoma is, on average, about 4 or 5 years younger than the average age of cancer 
diagnosis 70. The time length of the adenoma-carcinoma sequence varies among 
individuals 70. The whole period may range from 10 to 15 years 67. 
 
The removal of polyps within an endoscopy screening is the most effective prevention 
strategy to reduce the morbidity and mortality of CRC 29. However, polypectomy has 
been shown to be ineffective in inhibiting the progression of CRC carcinogenesis in 
around 24% of adenoma cases 76. Recent evidence also suggests that colonoscopy is 
more effective in reduction of colorectal cancer deaths associated with the distal colon, 
but not proximal colon 30–32. 
 
Adenomas are very common and the prevalence varies from 7.4 to 52.5% 77. A meta-
analysis of 18 studies reported that the pooled prevalence of adenomas was 30.2% in 
an average at-risk adult population 78. Approximately one third to one half of people will 
develop one or more adenomas in their lifetime 79. However, the risk of transformation 
from adenoma to carcinoma in an individual is low. Colonoscopy screening is used to 
locate and remove adenomas. Follow-up studies among participants with negative 
colonoscopy findings at baseline suggested the incidence rate of subsequent CRC 
within 10 years was 0.006% 80 while the CRC incidence rate after four years of follow up 
increased to around 0.6% for participants with advanced adenoma at the baseline 4. 
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Even though the malignancy rate for an adenoma is low, adenomas, compared with 
hyperplastic polyps, are most likely to develop into CRC 67.  
 
The characteristics of adenomas are important predictors for subsequent 
carcinogenesis. Adenoma size was one of main predictors in the progression to 
malignancy 70,71. Recent reviews indicated that the proportion of malignancy for 
adenomas under 1 cm is around 1.3%, the malignant potential for adenomas with a 
diameter of 1-2 cm increases to 9.7%, and nearly one third to half of large-size 
adenomas with a diameter over 2 cm develop to invasive cancers 70. In addition, villous 
adenoma was more likely to progress to carcinoma compared to tubular adenoma 70,71. 
Other known factors that predisposed to CRC were adenomas with advanced features, 
familial polyposis and ulcerative colitis 70. Advanced features include one of the 
following: >25% villous histology, size larger than 1 cm, and/or presence of high-grade 
dysplasia 81,82. The coexistence of two or more adenomas diagnosed at the same time 
or within 6 months is defined as synchronous adenomas 83. The incidence of advanced 
adenomas is higher in individuals who have synchronous adenomas 84. The U.S. 
population undergoing endoscopy screening has a prevalence of 3.4 to 7.6% for 
advanced adenomas 4. Sessile serrated polyps are saw-toothed and differ from 
traditional adenomas 4. The accurate prevalence for sessile serrated polyps is unknown 
but current best estimate was approximately 6 to 12% 4. Metachronous adenomas are 
adenomas detected half to one year after the previous polypectomy 83. Thus, it is 
possible that individuals with synchronous, large, advanced adenomas and sessile 
serrated polyps are at a higher risk of subsequent metachronous and advanced 
13 
 
adenomas as well as CRC 4. A cohort study based on private practice settings reported 
that the number of polyps at baseline was the only significant predictor for 
metachronous adenoma 85. Additionally, another cohort study in the Netherlands has 
reported that three or more adenomas identified at initial colonoscopy was a significant 
risk factor for further lesions at subsequent surveillance 81.    
 
CRC includes malignancies originating from the epithelial cells of the gastrointestinal 
tract, which includes the colon, rectum and appendix 82. The carcinogenesis progress is 
usually accumulated defects in tumor suppressor genes, oncogenes, and 
deoxyribonucleic acid (DNA) repair genes, which control cell growth, division, and 
apoptosis 86. However, the majority of genetic abnormalities that is involved in the 
formation of carcinoma is believed to start with somatic genetic mutations rather than 
heritable mutations 3. The genetic abnormalities can be caused by endogenous factors 
such as hormones and cellular nutrient metabolism or exogenous factors such as 
radiations, toxins and chemicals 3. Genetic components such as aforementioned 
accumulated defects may influence an individual’s propensity to develop polyps or CRC. 
Lifestyle or environmental factors could also initiate and promote the formation of polyps 
and subsequent CRC 87.  
 
3. Risk factors for colorectal neoplasia 
There are several unmodifiable risk factors for colorectal neoplasia such as age over 50 
years 55, male gender, a family history of CRC including multiple first-degree relatives 
with CRC or relatives with CRC diagnosed at a young age, and personal history of 
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chronic inflammatory bowel disease 84. A large number of studies have investigated 
modifiable risk factors associated with the development of and/or death due to CRC. 
Although it is inconsistent, behavioral factors which seem to decrease risk include being 
physically active, eating healthy, keeping an optimal body mass index (18.5 to 25), 
abstinence from smoking, no to light alcohol consumption, hormonal replacement 
therapy for postmenopausal women, regular endoscopy screening to remove polyps, 
and use of non- steroidal anti-inflammatory drugs (NSAIDs) 67. Oral intake of NSAIDs is 
considered to be one of the most promising prevention strategies for colorectal 
carcinogenesis chemoprevention 88. However, the long-term use of NSAIDs also carries 
risks for side effects.  
 
Over the past few decades, a large number of studies have investigated the role diet 
has on the risk of CRC. Nutrients such as fiber 89, vegetables 90, vitamin C and E 91, 
carotenoids and other antioxidants 90,92–94 have been extensively studied and the results 
are inconsistent. Recent large epidemiologic studies and/or clinical trials regarding the 
chemopreventive effects of these nutrients did not provide further evidence to support 
the potential benefits of these nutrients. Contrary to the original hypothesis, folic acid 
supplementation appeared to increase rather than reduce the risk of colorectal 
neoplasia 95. Similarly, although debatable, calcium alone or along with vitamin D 
probably protects against cancer 96–99. 
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4. Calcium and carcinogenesis  
4.1 Calcium intake and ionized calcium  
Calcium is a vital mineral in human metabolism and can be obtained from the diet 100. 
Ionized calcium balance is a comprehensive function of oral intake, intestinal absorption, 
renal reabsorption and skeletal modeling 101. Ionized calcium is vital for cellular 
functions and initiation of numerous physiological metabolic pathways 102. Intracellular 
calcium functions as a secondary messenger in pathways that involve secretion of 
many hormones and neurotransmitters 102.  
 
4.2 Mechanisms of calcium in relation to cancer 
The homeostasis of cancer is regulated by molecular-calcium pathways including: active 
energy-dependent calcium transporters, calcium-permeable ion channels, calcium-
binding and storage proteins, and calcium-dependent effectors 103. Despite 
inconsistencies, calcium may also function by reducing cell proliferation, stimulating 
differentiation, inducing apoptosis and regulating the cell-cycle of normal and tumor 
colorectal cells 104–107. Therefore, aberrant calcium signaling may be associated with 
uncontrolled proliferation, unregulated apoptosis, and metastasis of cancer cells. 
Although it may be assertive to state that aberrant calcium signaling is a cause of 
molecular and tissue homeostasis change and subsequent carcinogenesis; it would be 
better to consider aberrant calcium signaling as a dynamic consequence of genome, 
epigenetics, environmental factors, adaptation and compensation that triggers cancer 
initiation or progression103. In other words, mutations, over/under expression, 
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regulations of calcium handling toolkits of proteins are potential causes of aberrant 
calcium signaling in cancer 103.  
 
Newmark et al. first reported that calcium may have a chemopreventive effect on CRC 
in 1984 108.  Calcium is known to bind secondary bile acids and ionized fatty acids in the 
colon lumen to form insoluble calcium soaps, preventing bile acids and fatty acids from 
damaging the mucosa of the intestinal lumen by inhibiting their proliferative effects 108. 
Several studies 108–110 have supported that dietary calcium may decrease cytotoxicity, 
nitroso compounds, and lipoperoxidation in feces of dimethylhydrazine-initiated rats and 
human volunteers, thereby subsequently reducing CRC risk attributed to processed 
meat intake.  
 
4.3 Epidemiological studies on calcium and colorectal neoplasia 
A few studies have reported a significant protective effect of calcium on colorectal 
neoplasia 18,110,11,8 while a few studies have not detected such beneficial effect 125,126. A 
pooled-analysis of 10 cohort studies suggested that the highest quintile of total calcium 
consumption from both dietary and supplemental sources may confer a 14% reduction 
of risk in CRC versus the lowest quintile, with the association only being significant 
among people with high intake of vitamin D 22. Epidemiologic studies found high calcium 
consumption was associated with approximate 20-30% reduction in risk of colorectal 
adenoma 17–20, metachronous  colorectal adenoma 23–25, and overall CRC risk 21,22. The 
protective effect of calcium supplementation may extend up to 5 years after cessation of 
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active treatment 127. Figure 2.3 is a hypothesized diagram of calcium intake in relation 
to adenoma-carcinoma sequence.  
 
Consistent with the results from these epidemiologic studies, two large intervention trials 
observed that calcium supplementation moderately reduced the risk of metachronous 
colorectal adenoma 23,24, while one trial found that this protective effect may only be 
present in those with a high blood level of vitamin D 25. Baron et al. 127 found in the 
observational phase of a clinical trial that the protective effect of calcium 
supplementation on metachronous colorectal adenoma rate extends up to 5 years after 
cessation of active treatment. However, results from a very recent large-scale 
randomized clinical trial (Women's Health Initiative, WHI) do not support an effect of 
calcium plus vitamin D (CaD) supplementation for 7 years on the incidence of CRC 15. 
An updated analysis of WHI study showed that among participants with no personal 
calcium or vitamin D supplements, CaD was significantly associated with decrease the 
risk of total cancers and non-significantly reduces the risk of CRC ; however, CaD did 
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Figure 2.3 Calcium intake on adenoma-carcinoma sequence derived from Morán A et al. 2010 
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not alter cancer risk in women who took personal calcium or vitamin D supplements 128. 
Clinical trials regarding calcium supplementation for at least 6 months on risk of 
colorectal neoplasia is summarized in Table 2.1.  
 
Calcium sensing receptor (CaSR), mainly expressed in the parathyroid gland and the 
renal tubules of the kidney, controls calcium homeostasis by regulating the release of 
parathyroid hormone and by inhibiting the reabsorption of calcium in the kidney 111,112. 
Polymorphisms of the CaSR gene were reported to affect serum calcium concentrations 
111,113,114. However, genetic epidemiological studies have reported both significant 115–119 
and null association 120–123 between variant alleles of the CaSR gene and risk of 
colorectal tumors. A meta-analysis 124 of the CaSR gene found that polymorphisms of 
rs1042636 were associated with reduced risk of proximal and distal CRC; variant alleles 
of rs1801726 were associated with increased risk of distal but not proximal CRC; and 
rs1801725 polymorphisms were not associated with risk of CRC.  
 
5. Magnesium and carcinogenesis 
Magnesium, involved in more than 300 metabolic functions 129, is an essential element 
for the body. Similar to the distribution of calcium in humans, approximately 60% of the 
magnesium is reserved in the bones and teeth, 20% in the muscle tissue, 19% in soft 
tissues such as heart, brain, liver and kidney, and less than 1% in the extracellular fluid 
including erythrocytes and serum 130. An analysis of data from the National Health and 
Nutrition Examination Survey (NHANES) of 2005-2006 found that a majority of 
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Table 2.1 Randomized clinical trials of calcium supplementation and the risk of colorectal neoplasia 
Authors 
Study 
characteristics 
Interventions Outcomes 
Baseline 
calcium 
(mg/day) 
Main findings 
Highest vs lowest category of calcium 
OR (95%CI) 
Baron J,  
et al. 
2015 
N=2259, 
Multicenter, 
Patients aged 
45-75 and with 
recently 
diagnosed 
adenomas 
and no known 
colorectal 
polyps 
remaining 
after complete 
colonoscopy 
 
Daily vitamin D3 
(1000 IU)  
N=420, 
calcium as 
carbonate (1200 
mg)  N=419, 
both  N=421, 
or neither  
N=415, for a 
mean duration 
of 4 years 
Colorectal 
metachronous 
adenoma 
-- Ca vs no Ca: 0.95 (0.85-1.06) 
 
Ca by baseline Ca≤597 mg/day:  
0.90 (0.78-1.05) 
Ca by baseline Ca>597 mg/day:  
0.97 (0.82-1.15) 
 
Ca by  Ca:Mg ≤ median a: 0.68 (0.52, 0.90) 
Ca by  Ca:Mg > median a: 0.98 (0.75, 1.28) 
 
 
 
Bonithon
Kopp, 
2000 
665 patients 
with a history 
colorectal 
adenomas 
2 g elemental 
calcium, or 3.5 g 
fibre, or placebo  
daily for 3 years 
Colorectal 
metachronous 
adenoma 
 
944±364 
 
Calcium /placebo: 0.66 (0.38,1.17) 
a: results among 930 subjects were previously published by  Dai Q11, 2012. 
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Americans at all ages have less magnesium intake than recommended daily intakes 131. 
Adult men aged 71 years and older and adolescent females are most likely to have low 
magnesium intakes 131. A low magnesium diet in the long term is associated with 
reduced serum magnesium and intracellular free magnesium in red blood cells 132.   
 
Magnesium is a necessary nutrient needed to provide energy supply to cells. It plays a 
vital role in the active transport of calcium and potassium ions across cell membranes 
129. Magnesium is also inversely associated with anti-inflammatory biomarkers 133. 
Larsson et al. 134 proposed evidence that magnesium may prevent colon cancer by 
reducing oxidative stress, improving insulin sensitivity, or by other means of decreasing 
colonic epithelial cell proliferation. 
 
Fewer studies have investigated possible associations between magnesium and 
colorectal neoplasia than have been conducted for association with calcium. A case-
control study found that magnesium level in drinking water was not associated with 
death from cancers of the colon  135 and rectum 136. Two prospective studies observed 
an inverse association between total magnesium intake and incident CRC 134,137, 
although one study reported that the inverse association was only limited to colon 
cancer 137. A cohort study in Japanese has indicated the inverse association was only 
significant for men but not for women 138. However, two prospective studies have 
reported null results 139,140.  
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6. Calcium to magnesium ratio 
Micronutrients of calcium, magnesium, phosphorus, and vitamin D share common food 
sources and are considered to be “metabolically interactive” 141. Magnesium has an 
active role in adenosine triphosphatase, which is the energy source for ion exchange 
pump 142. Intracellular magnesium deficiency may result in an increase in intracellular 
calcium 143. Examining the effect of a single micronutrient without taking into account 
the influence of complementary or opposing nutrients may lead to residual confounding 
and incomplete risk assessment 144.  
 
Calcium and magnesium share the same homeostatic regulatory system 45 primarily 
through absorption in intestine and reabsorption in kidney to keep the balance of Ca:Mg 
45,46.  Nevertheless, magnesium and calcium compete with each other in (re)absorption 
and transport 47–51. High calcium intake reduces absorption of both magnesium and 
calcium 145 whereas moderate magnesium deprivation results in negative magnesium 
balance while increased calcium retention 146. Extracellular concentration of magnesium 
has been shown to competitively inhibit the transportation of calcium 147. In addition, 
magnesium supplementation has been associated with increased urinary calcium 
excretion when calcium intake was less than 800 mg/day 148, suggesting that 
magnesium may suppress calcium reabsorption when Ca:Mg intake ratio is very low 28. 
Therefore, the Ca:Mg intake ratio may take an important role in regulating calcium and 
magnesium (re)absorption. Several recent studies have postulated and preliminarily 
confirmed that the dietary ratio of calcium to magnesium modifies the effects of calcium 
and magnesium intakes on carcinogenesis 17,28,149. In addition, one animal study has 
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indicated that the severity of inflammation caused by magnesium deficiency could be 
reduced by calcium deficiency 52. Growing evidence strongly suggestes that the balance 
of calcium and magnesium plays an essential role in many diseases 52. Considering that 
more than 45% of the U.S. population aged 40 or older are users of calcium 
supplements, an investigation into the balance of calcium and magnesium (Ca:Mg ratio) 
in colorectal carcinogenesis is particularly important.   
 
6.1 Calcium to magnesium ratio and chronic diseases 
Magnesium and calcium also potentially antagonize each other in many physiologic 
activities 47,48, including insulin resistance 150, oxidative stress 151, systematic 
inflammation 134, cell proliferation, differentiation, angiogenesis, and apoptosis 
47,49,52,108,152,153. These activities may subsequently result in carcinogenesis. Dai et al. 
first reported that dietary intake ratio of Ca:Mg modified the association between intakes 
of calcium and magnesium in relation to colorectal adenoma 17. Ca:Mg ratio also 
interacted with a functional common polymorphism in the gene encoding TRPM7, a 
channel regulating Ca2+ and Mg2+ 154,  in relation to both colorectal adenoma and 
hyperplastic polyps 17. A subsequent randomized clinical trial reported that calcium 
supplementation only reduced risk of colorectal metachronous adenoma when the 
baseline Ca:Mg was less than or equal to 2.63 26. In addition, a high serum Ca:Mg was 
significantly associated with an increased risk of high-grade prostate cancer even after 
adjusting for serum levels of calcium and magnesium 149. In support of these findings, 
one case-control study in Belgians has reported a high calcium but low magnesium was 
associated with increased risk of bladder cancer 144. East Asian populations have a 
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similar intake level of magnesium as the U.S. population 155,156. A high magnesium 
intake at U.S. recommended dietary allowance level was associated with increased risk 
of total mortality, cardiovascular diseases and cancer mortality in East-Asian 
populations with a very low Ca:Mg ratio (1.7(median)) 28,156; whereas in the U.S. 
population with a high Ca:Mg ratio (median=3.0) 155, high magnesium intake was 
significantly linked to reduced risk of these diseases 134,139. In the same cohort study 
conducted in east Asians, the association between intakes of calcium and magnesium 
with the risk of total, cardiovascular disease and/or cancer mortalities were modified by 
Ca:Mg ratio, but not by calcium or magnesium intake alone 28. These findings were 
consistent with that from the Nurses’ Health Study which reported that the interaction 
between total calcium and magnesium intakes was not statistically significant in relation 
to the risk of CRC incidence 139. The direct associations between Ca:Mg ratio and 
chronic diseases are summarized in Table 2.2 and the modification effect of Ca:Mg 
ratio on associations between calcium intake or serum calcium levels and the risk of 
common chronic diseases are presented in Table 2.3. 
 
7. Hypothesized explanations for inconsistent associations between calcium and 
colorectal neoplasia  
Factors such as the dose and duration of calcium and vitamin D treatment have been 
proposed to explain the inconsistency in findings across studies 99,157. Prospective 
studies of CRC and calcium intake suggested that 600-1000mg of calcium per day may 
be ideal for CRC risk reduction, with no further protection beyond this range 158. The 
Nurses’ Health Study and the Health Professionals Follow-up Study also indicated a  
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Table 2.2 The direct effect of Ca:Mg ratio on the risk of common chronic diseases 
Authors Population 
Exposures 
Components 
Outcomes Study Design 
Main findings 
Highest vs lowest category of calcium 
OR (95%CI) 
Dietary  
Ca/Mg 
Serum  
Ca/Mg 
Dai Q, et 
al1. 
2010 
494 NMHS 
participants 
including 
331 cases 
and 163 
controls  
-- Yes  Prostate 
cancer cases 
 
Case-control Higher VS lower Ca:Mg ratio:  
2.81 (1.24, 6.36) 
Takata Y, et 
al. 2013 
71, 267 
females  
From 
SWHS 
in China   
Yes -- Lung cancer Cohort  Higher VS lower Ca:Mg ratio:  
0.62 (0.47, 0.82) 
Sun, Y, et 
al18. 2013 
-- -- Yes  Proliferation  
of prostate 
cancer cells 
In-vitro study An increase in the serum ratio of Ca2+/Mg2+ 
promoted proliferation for the 
initiation/progression of prostate cancer 
cells by activating TRPM7 channel 
Ziniewicz 
HK, 2015 
48 neonates  -- Yes Cardiovascul
ar disease 
markers,  
insulin 
sensitivity/re
sistance 
markers (e.g. 
glucose, 
insulin, 
HOMA) 
Cross-sectional 
study  
The Ca:Mg ratio is negatively related to 
arylesterase (AE) (p<0.01),  AE/HDL-c 
(p<0.05), and low levels of insulin 
 
Serum calcium negative correlated with 
HDL-c (p<0.05), arylesterase (AE) (p<0.01), 
the Apo A1/Apo B (p<0.05) and AE/HDL-c 
(p<0.05) ratios 
 
Neonates within the highest quartile for Mg 
displayed significantly higher levels of LDL-
c and homocysteine (p<0.05) 
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Table 2.3 Studies of the modification effect of Ca:Mg ratio on associations between calcium and the risk of diseases 
Authors Population 
Exposures 
Components Outcomes Study Design 
Main findings 
Highest vs lowest category of calcium 
OR (95%CI) Diet Supplement 
Dai Q, et 
al2. 2007 
898 cases 
and 1306 
controls 
from the 
TCPS  
Yes Yes  Colorectal 
adenoma 
cases , 
hyperplastic 
polyp cases  
Case-control Diet Ca: 1.12 (0.76, 1.65) 
Total Ca: 0.98 (0.68, 1.40) 
Total Ca by  Ca:Mg ≤ 2.78: 0.72 (0.30, 1.69) 
Total Ca by  Ca:Mg > 2.78: 1.32 (0.69, 2.53) 
Dai Q11. 
2012 
930 
subjects 
-- Yes  
(Treatment) 
Colorectal 
metachrono
us adenoma  
Randomized 
clinical trials  
Ca by  Ca:Mg ≤ median: 0.68 (0.52, 0.90) 
Ca by  Ca:Mg > median: 0.98 (0.75, 1.28) 
Dai et al, 
2013 
Over 
130,000 
participants. 
From 
SWHS 
and SMHS  
in China   
Yes  Yes  All-cause 
mortality 
and 
disease-
specific 
mortality 
Cohort  Men 
  Total mortality by  Ca:Mg ≤1.7: 0.95 (0.66, 1.36) 
  Total mortality by  Ca:Mg >1.7: 0.59 (0.44, 0.80) 
  CHD mortality by  Ca:Mg ≤1.7: 1.64 (0.73, 3.70) 
  CHD mortality by  Ca/Mg>1.7: 0.48 (0.21, 1.09) 
Women 
  Total mortality by  Ca:Mg ≤1.7: 1.03 (0.78, 1.36) 
  Total mortality by  Ca:Mg >1.7: 1.06 (0.81, 1.39) 
  CHD mortality by  Ca:Mg ≤1.7: 1.92 (1.00, 3.70) 
  CHD mortality by  Ca/Mg>1.7: 0.85 (0.41, 1.76) 
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daily intake of 700-800mg calcium is beneficial for CRC prevention 90. These findings 
may explain the null effects found in the WHI, in which women had a total calcium 
intake of approximately 2150 mg/day (1000 mg of Ca carbonate plus a baseline mean 
intake of 1151 mg) 158, which is far from the beneficial range summarized from 
prospective studies. However, this does not explain why another clinical trial using 
similar or even higher levels of calcium supplementation (1200 mg/day) and total 
calcium intake (>2100 mg/day) found calcium intake was associated with reduced risk 
of metachronous adenoma 23. It is plausible that there is a population difference. 
Participants recruited in these metachronous adenoma trials have a high risk of 
colorectal polyps, whereas participants included in the WHI are generally post-
menopausal female subjects.  
 
Furthermore, evidence from earlier studies suggested that there is a substantial 
variation of the ability to (re)absorb calcium in healthy people, which is mostly attributed 
to genetic variation159. Although not consistent, several previous studies found the 
association between calcium intake and CRC risk may be modified by genetic 
polymorphisms in vitamin D receptor 160,161 and calcium-sensing receptor 162,163. Dai et 
al. also reported the association of calcium intake and risk of colorectal adenoma may 
differ by polymorphism in the transient receptor potential melastatin 7 (TRPM7) gene 17. 
Moreover, high calcium intake was significantly associated with reduced adenoma risk 
among carriers with variant alleles in genes of potassium channel, inwardly rectifying 
subfamily J, member 1 (KCNJ1) and solute carrier family 12, member 1 (SLC12A1) 164. 
Future research on adequate nutrients intake and targeting for subpopulations with high 
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risk such as certain genetic profiles (gene-nutrient interactions) is going to advance the 
field of cancer chemoprevention and prevention of other common chronic diseases. 
 
It is also reasonable to investigate whether the balance of calcium and other nutrients 
could help to explain the discrepancy. The beneficial effect of nutrient supplementation 
was reported in a large clinical trial conducted in a population in China, at high risk of 
nutritional deficiency 165. This indicated that supplementation of nutrients may only be 
effective among high-risk populations with nutritional deficiency. Furthermore, from 
these trials, we learned that excessive supplementation of nutrients also could lead to 
adverse effects 166. High levels of calcium consumption or serum levels were associated 
with a reduced risk of CRC or adenoma22 but an increased risk of advanced/fatal 
prostate cancer 167–174. Growing evidence showed that some nutrients or metals, 
including calcium, showed protective effects on cancer at a normal range while harmful 
effects at a high dose 165. These evidences further support the hypothesis of nutrients 
balance. The Ca:Mg intake ratio, a hypothesized marker for calcium and magnesium 
balance, has not been considered in most of previous studies, except for some recent 
publications 17,26,  in which the inverse association between calcium intake and 
adenoma prevalence and recurrence only appeared when the Ca:Mg intake ratio is low. 
Thus, studies on Ca:Mg ratio 17,26,149 provide further evidence for the theory of nutrients 
balance.  
 
8. Chronic diseases related to colorectal neoplasia 
Epidemiological studies have shown that diabetes 34–37 and metabolic syndrome 38–40 
are strongly associated with risk for CRC development. The metabolic syndrome is a 
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cluster of metabolic abnormalities including dyslipidemia (hypertriglyceridemia and 
decreased fasting serum high-density lipoprotein cholesterols (HDL-c)), glucose 
intolerance, hypertension, insulin resistance, and central obesity. Higher blood pressure, 
total cholesterol, triglyceride, and lower HDL-c levels have been associated with 
increased risk of colorectal adenoma 175. Hypertension, one of main components in 
metabolic syndrome, is a risk factor for recurrent colorectal adenoma 176. A recent meta-
analysis has reported that metabolic syndrome was associated with 34% increase in the 
risk of colorectal neoplasia 177. Diabetes was associated with an elevated risk for both 
proximal and distal colon adenomas, but was more strongly associated with proximal 
colon adenoma and with large adenomas (≥5 mm in diameter) 178.The mechanism 
underlying these relations is not completely understood.  
 
B. The lipid profile 
1. The composition and physical function of lipid profile  
The lipid profile or lipid panel is a pattern of lipids in the blood, which is also a group of 
blood tests used to assess the risk of developing cardiovascular disease or to monitor 
treatment effect. Typically, the lipid profile includes low-density lipoprotein cholesterol 
(LDL-c), HDL-c, triglycerides, and total cholesterol 179. Some lipid measurements also 
include very low-density lipoprotein (VLDL) if the LDL-c is very high.  
 
LDL-c mainly facilitates the transportation of fat and a small amount protein from liver to 
other peripheral tissues 179. VLDL is produced in the liver primarily from dietary 
triglycerides 179. It is usually estimated by a percentage of the triglyceride. The main 
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function of VLDL is to distribute the triglyceride produced in the liver. HDL-c is called 
"good" cholesterol 179. It was postulated that HDL-c helps transport cholesterol from 
peripheral tissues back to the liver, where the majority of cholesterol were catabolized 
and excreted 180–182. Higher levels of HDL-c is associated with lower risk for 
cardiovascular disease 179. Triglycerides are the fats absorbed in the blood through diet 
or made by the liver in response to diets rich in sugars, refined carbohydrates, or fats 179. 
The body utilizes triglycerides to store energy and provide a source energy to muscles. 
Only small amounts are found in the blood. Cholesterol is necessary for constructing the 
lipid layers in cells and for hormone production 179. Excessive blood cholesterol 
accelerates blockages of inside arteries, which can increase risk for cardiovascular 
disease. 
 
2. The development of cardiovascular disease 
Initially, cholesterol deposits and accumulates in the arteries that supply to the heart 183. 
With gradual accumulation over time, the lumen of the artery begin to narrow. This 
process is called atherosclerosis. Atherosclerosis in the coronary artery is known as 
coronary artery disease, which is the most common type of cardiovascular disease 184. 
 
3. Contributing factors of cardiovascular heart disease 
Heart disease is the leading cause of death in the U.S. 197. Multiple factors (i.e. diabetes, 
smoking, high blood pressure, obesity, physical inactivity, and genetics) could affect 
lipid panel and are deemed as contributing factors of cardiovascular disease 198. 
Greater control of risk factors and improved treatment are considered main contributors 
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to the reduction of mortality 199,200. The administration of statin treatment is associated 
with a 20% reduction in total cholesterol, 28% reduction in LDL-c, 13% reduction in 
triglycerides, and 5% increase in HDL-c 188. Combinations of fibrate, niacin (North and 
South America), omega-3 fatty acids or ezetimibe with a statin further reduced 
cardiovascular risk 201. However, a large residual risk of cardiovascular disease remains 
unexplained 187,201.  
 
4. Magnesium and lipids  
Kobayashi first reported in an ecological study that the hardness of drinking water was 
inversely associated with mortality rate due to stroke 305. Since then, numerous studies 
have investigated the associations of calcium and magnesium content in drinking water 
306 or dietary intake 213,220,236,307–309 on lipid metabolism and the risk of subsequent 
cardiovascular disease. Early observational studies reported positive 227, inverse 228, 
and null 229 associations between blood magnesium and cholesterol. 
 
Early experimental data from animal studies have shown that magnesium plays a role in 
the pathogenesis and treatment of vascular disease 202–204. In several species, 
magnesium deficiency was associated with marked hypertriglyceridemia, 
hypercholesterolemia, increased LDL-c, and a decrease in the percentage of 
cholesterol transported by HDL-c 202–204. Increased magnesium intake has been shown 
to improve insulin sensitivity, hyperglycemia, hyperlipidemia, and oxidative stress and 
has been shown to reduce lipid peroxidation in fructose-fed rats 205.These findings 
indicate that magnesium deficiency worsens several parameters of lipids.  
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A number of small-scale clinical trials have also generated inconsistent results on the 
effects of magnesium supplementation on lipid profile. Magnesium supplementation 
significantly improved lipid profile, including a reduction in total cholesterol, LDL-c and 
triglycerides in a few trials 206,207, but not in others 208,209 210,211. A meta-analysis of nine 
clinical trials found magnesium treatment significantly, but weakly, increased HDL-c, 
and had no effect on LDL-c and triglycerides 212. A clinical trial among patients with type 
2 diabetes mellitus has observed a significant fall in serum total cholesterol, LDL-c and 
triglycerides as well as a rise in HDL-c levels in 4 to 8 weeks after the initiation of 
magnesium supplementation. This effect continued to be observed till the end of the 
study 12 weeks 213. However, none of these previous studies have considered the 
Ca:Mg balance and this may explain a part of the inconsistency in previous studies.  
 
5. Calcium and magnesium with lipid  
High calcium supplementation was linked to increased risk of myocardial infarction 
232,233. Conversely, some studies found that high calcium from dietary sources were 
associated with a reduced risk of cardiovascular disease 234,235. Two grams of calcium 
carbonate supplementation was associated with deceased triglycerides and possibly 
total cholesterol in a small clinical trial with 92 colorectal adenoma patient 236. Previous 
intervention trials also generated inconsistent results on the effect of calcium 
supplementation on lipid profile 307,313,314. It was hypothesized that dietary sources of 
calcium usually goes together with reasonably high magnesium dietary intake, which 
leads to a reasonable Ca:Mg ratio. In contrast, calcium supplements alone substantially 
increase the Ca:Mg ratio. This may explain the differential effects of calcium from 
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dietary 234,235 and supplemental sources 232,233 on cardiovascular disease risk and 
mortality.   
 
Experimental studies have suggested that the balance between calcium and 
magnesium may modify markers of lipid profile. Evidence from animal studies reported 
that calcium-adequate and magnesium-deficient diets lead to increases in heart lipid 
peroxidation, plasma levels of triglycerides and inflammatory markers; whereas a 
combination of calcium-deficient and magnesium-deficient diets cause significant 
reductions in inflammatory markers, lipid peroxidation and a normalization of plasma 
triglyceride concentration 52,53. These findings highlight the critical role of the dietary 
Ca:Mg balance in the development of dyslipidemia and subsequent cardiovascular 
disease.  
 
Patients with cardiovascular disease such as variant angina 237 and myocardial 
infarction 238 usually have magnesium deficiency 239.  Calcium channel-blocker therapy 
was proved to increase serum or fluid magnesium 237,238. Dai et al. proposed that 
calcium and/or magnesium intake may be associated with an increased risk of 
cardiovascular disease mortality if the Ca:Mg ratio is either ≥2.6 or ≤1.7, but associated 
with a reduced risk or no risk when the Ca:Mg ratio is between 1.7 and 2.6 28. The 
modifying effect of the Ca:Mg ratio may explain the inconsistent results of previous 
studies pertaining to calcium and magnesium intakes and cardiovascular disease risk 
216,220 or between magnesium supplementation and lipid profile change 206–209,211,212.   
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Previous trials of magnesium supplementation enrolled subjects with both high and low 
Ca:Mg ratios; the high doses of magnesium generally used in these trials may have 
resulted in a very low Ca:Mg ratio (<1.7), particularly for those with a low ratio at 
baseline 212. These findings indicate the critical role of the dietary Ca:Mg balance in 
cardiovascular disease development. In other words, the effects of dietary magnesium 
and calcium on cardiovascular disease may differ by Ca:Mg intake ratio levels in the 
diet. 
 
6. Potential mechanisms for magnesium efficacy on cardiovascular disease  
The enzyme activity of lecithin cholesterol acyltransferase (LCAT) 240 and lipoprotein 
lipase (LPL) 202, which lowers triglycerides levels and raises HDL-c levels, requires the 
involvement of magnesium 241. The lipid lowering effect of magnesium could be 
attributed to improved activity of LPL or insulin, or decreased actions of lipogenic liver 
enzymes 242,243.  Moreover, magnesium2+- adenosine triphosphate (ATP) determines the 
rate-limiting enzyme in the cholesterol biosynthesis, which is associated with cholesterol 
levels 241. In the pathway of cholesterol biosynthesis, the conversion of 2-hydroxy-3-
methyl-glutaryl-coenzyme A (HMG-CoA) to mevalonate requires the enzyme, HMG-CoA 
reductase, which is the rate-limiting enzyme 244.  The statins and magnesium inhibit that 
enzyme 244.  
 
The role of Ca:Mg intake ratio in lipid metabolism is less frequently studied. Thus, there 
are no reports of whether the change of Ca:Mg intake ratio by magnesium 
supplementation may have a role in lipid metabolism. No previous studies investigated 
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the hypothesis that lipid profile is an potential intermediate biomarker between Ca:Mg 
ratio and risk of colorectal neoplasia and cardiovascular disease. 
 
C. Uric acid  
1. Known factors that affect uric acid 
Uric acid is a metabolic product of purine nucleotides. The serum uric acid reflects the 
balance between production and excretion 245. Both exogenous (dietary) and 
endogenous purines are the major sources of uric acid for humans. Approximately 70% 
of daily excretion of uric acid is through the kidney 246.   
 
1.1 Increase of uric acid 
Diets rich in purines, high-fructose corn syrup, and table sugar are a risk factor of 
elevated uric acid 247,248. Liver and kidney 249 have a high amount of purines. A 
moderate amount of purines is found in meats such as beef, lamb, pork, poultry and 
seafood 249. Certain vegetables such as asparagus, beans, cauliflower, green peas, 
mushrooms, oatmeal, spinach, etc., contain a moderate level of purines 249.  In addition, 
hereditary factors, rapid weight loss, and diuretic medications could cause elevation of 
uric acid 250. Certain drugs including thiazide diuretics and inosine can increase uric acid 
levels in the blood by interfering with renal clearance 251. Behavioral factors such as 
fasting and rapid weight loss can temporarily elevate uric acid levels. Correcting low or 
deficient zinc levels can help elevate serum uric acid in Wilson’s disease by 
ameliorating liver function and uric acid synthesis 252. A higher serum uric acid level was 
associated with diabetes mellitus, hypertension, and increased triglycerides level 43.  
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1.2 Decrease of uric acid 
A purine-free diet was associated with approximately 35% decline in plasma urate for 
healthy males 253.  A cohort study with hemodialysis patients has indicated that factors 
such as cardiovascular diseases, increased age, creatinine, fasting blood glucose, 
corrected calcium, phosphate, corrected calcium plus phosphate product, and LDL-c 
levels were associated with lower serum uric acid levels 43.  
 
2. Uric acid and disease  
Abnormal concentrations of uric acid may be an indicator of certain diseases 245. 
Hyperuricemia is associated with a variety of diseases such as all-site cancer incidence 
and mortality 321, hypertension 254–256, cardiovascular disease 257–260, diabetes 261, gout, 
kidney disease 262–264, and obesity 265. Hypouricemia was linked with multiple sclerosis 
266,267. Although epidemiologic studies have indicated rich evidence that elevated serum 
uric acid is independently associated with metabolic abnormalities, the mechanisms 
behind these associations have not been fully understood and are not well-established 
268.  
 
2.1 Magnesium, uric acid and type 2 diabetes 
Whether elevated serum uric acid is a risk factor for diabetes has long been a matter of 
debate. Even since the early 1980s, uric acid has been associated with the 
development of diabetes although these associations were not adjusted for potential 
confounders 269. Moreover, this report showed that serum uric acid levels were higher in 
prediabetics than in nondiabetics 269,270. A prospective follow-up study showed high 
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serum uric acid measured at the baseline is associated with higher risk of type 2 
diabetes, independent of obesity, dyslipidemia, and hypertension 271. For each 1 mg/dl 
increment in uric acid levels, approximately 60% increased risk of incident type 2 
diabetes was observed 272. Although statistically significant associations have been 
extensively reported, one study in Japanese men reported a null association 273. 
Another study has found a negative association between serum uric acid and diabetes 
274. Changes in serum urate (salt of uric acid) were associated with changes in serum 
magnesium in women with type 2 diabetes and non-diabetic men 275.  
 
2.2 Magnesium, uric acid and metabolic syndrome 
Hyperuricemia, a relatively new risk factor of metabolic syndrome, has been associated 
with a higher prevalence of metabolic syndrome 261. A study has suggested fructose-
induced hyperuricemia may play a pathogenic role in metabolic syndrome 276. This is 
consistent with the increased consumption of fructose-containing beverages (such as 
fruit juices and soft drinks sweetened with sugar and high-fructose corn syrup) and the 
epidemic of diabetes and obesity in recent decades 277. Serum uric acid is closely 
associated with metabolic syndrome in females than males 278. One study has 
demonstrated elevated uric acid and lower serum magnesium were significantly 
associated with insulin resistance 279.   
 
2.3 Calcium, magnesium, uric acid and cardiovascular disease 
Viazzi et al. found that serum uric acid was associated with a positive history of 
cardiovascular disease and high Framingham risk score, which is independent of 
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metabolic syndrome 280. A meta-analysis reported that 1 mg/dl increase in uric acid level 
was associated with 13% increased risk of incident hypertension 281. Elevated serum 
uric acid level a is positively associated with cardiovascular mortality 257. In addition, 
elevated levels of serum uric acid was associated with the presence of coronary artery 
calcium 42, a marker of atherosclerosis. A number of studies adjusted for multiple risk 
factors suggested that uric acid may be an independent risk factor for cardiovascular 
disease 257,282–284. Another set of studies have indicated that uric acid is not independent 
of other established risk factors, especially hypertension, for the development of 
cardiovascular disease 285–288. The role of uric acid in cardiovascular disease is still 
debated 265.  
 
However, the majority of studies evaluating uric acid are observational studies. 
Moreover, our previous findings suggest a modifying effect of the Ca:Mg ratio on 
associations between calcium or magnesium intake and risk of colorectal 17,26 and 
esophagenal neoplasia 27, total, cardiovascular disease and cancer mortalities 28. To 
our knowledge, no previous randomized trial has evaluated the effect of magnesium on 
uric acid status. Further, no previous study has examined whether the Ca:Mg intake 
ratio plays a role in uric acid metabolism and whether uric acid is an intermediate 
biomarker between Ca:Mg ratio and risk of colorectal neoplasia and cardiovascular 
disease.  
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Chapter 3. Research strategies 
A. The Prostate, Lung, Colorectal, and Ovarian (PLCO) screening trial (project A) 
1. Study design: overall description   
The PLCO is a ten-study-center, randomized, controlled trial comparing cancer 
screening tests and usual care to determine the effects of screening on cancer-related 
mortality. The details of the study design were described elsewhere 289,290. Nine of ten 
study centers (Denver, CO; Detroit, MI; Honolulu, HI; Marshfield, WI; Minneapolis, MN; 
Pittsburgh, PA; Salt Lake City, UT; St. Louis, MO; and Washington, DC) began 
enrollment of eligible participants in November 1993. The University of Alabama began 
enrollment in January 1998. About 155,000 subjects were recruited between November 
1993 and July 2001. After stratification by age and gender within each study center, 
participants were individually randomized to the intervention arm or control arm in equal 
proportions (block randomization). The date of enrollment is the date of randomization. 
Participants assigned to the intervention arm were invited to receive screening exams 
for prostate, lung, colorectal and ovarian cancers, whereas participants assigned to the 
control arm received routine medical care. The screening methods were digital rectal 
examination plus serum prostate-specific antigen (for prostate), chest X-ray (for lung), 
flexible 60-cm sigmoidoscopy (FSG) (for colorectum), cancer antigen 125 and 
transvaginal ultrasound (for ovary). The data analyses for this proposed project were 
primarily within the screening arm of the PLCO trial (n=77,444). The control arm of the 
PLCO initially had 77,453 participants.   
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2. Study population 
According the original PLCO study design 289,290, the exclusion criteria used to select 
eligible subjects were listed as follows: 
1) Aged < 60 or >74 at the time of randomization; Beginning in January 1996, 
participants aged < 55 or >74 at the time of randomization were excluded; 
2) Under cancer treatment (excluding basal and squamous cell skin cancer) at 
the entry of the trial; 
3) With known diagnosis of colorectal, lung, ovarian or prostate cancer; 
4) With previous surgical removal of the entire prostate, one lung or the entire 
colon; 
5) With prior surgical removal of both ovaries. Starting in October 1995, this 
criteria was deleted; 
6) Participating in another cancer screening or cancer primary prevention trial; 
7) Males who have taken Proscar in the past 6 months; 
8) Starting in April 1995, males who had more than one prostate specific antigen 
(PSA) test in the three years prior to enrollment; 
9) Starting in April 1995, participants who had a colonoscopy, sigmoidoscopy, or 
barium enema in the three years prior to enrollment; 
10) Unable or unwilling to provide informed consent. 
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3. Data collection 
3.1 Baseline Questionnaire (BQ) 
At the entry of the trial, participants were asked to complete a BQ. The BQ collected 
information on demography (e.g., age, sex, race, education, and marital status), family 
cancer history, personal medical history (including the history of colorectal polyp, 
nonsteroidal anti-inflammatory drugs use, cancer screening history within 3 years), 
anthropometry (height, weight), lifestyle factors including smoking history and physical 
activities. In the intervention arm, 75,611 (97.6%) of participants finished the BQ. In the 
control arm, 74,366 (96.0%) of subjects has a valid BQ.  
 
3.2 Dietary Information 
3.2.1 Dietary Questionnaire (DQX) 
The DQX which included 137 food items at baseline was administered among 
intervention arm participants to obtain dietary intake over the 12 months before 
enrollment, and 14 questions about supplement intake. In the intervention arm, 60,358 
(77.9%) of participants completed the DQX and 1,721 of subjects were further excluded 
because of invalid DQX. A questionnaire was invalid for any of the following four criteria 
291: 1) Missing date of completion; 2) Death before the completion of the DQX; 3) Eight 
or more missing items in food frequency questionnaire; and 4) Extreme (highest or 
lowest 1% for each gender) caloric intake. 
 
3.2.2 Dietary History Questionnaire (DHQ) 
In December 1998, a second dietary questionnaire, the DHQ with 114 food items, was 
implemented. The DHQ was administered to participants of the control arm at T0 (time 
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of year 0) and intervention arm at T3 (time of year 3). Participants who had already 
passed these windows received the DHQ at their randomization anniversary in either 
1999 or 2000. Among enrolled participants, 111, 477 (72.0%) individuals have 
completed the DHQ. Four criteria were used to confirm the validation of questionnaires: 
1) A date of completion must exist; 2) The date of completion must not be later than the 
date of death; 3) Fewer than 8 missing frequencies; 4) Caloric intake is within normal 
range (excluding top and bottom 1% for each gender). Only valid food frequency 
questionnaires (N=106,522) were used for dietary analyses, of which 58,637 were in the 
intervention arm and 47,885 were in the control arm.  
 
4. Nutrients  
4.1 Dietary nutrients 
Usual frequency of intake (less than once a month, once a month, twice to thrice a 
month, once a week, twice a week, three to four times a week, five to six times a week, 
once a day, two or more times a day) and portion size (small, medium, large) were 
queried. The usual dietary intakes of nutrients, including calcium, magnesium, and 
vitamin D, were derived from frequency and portion-size responses from DHQ and DQX, 
in which nutrient values per portion were multiplied by the daily frequency of intake and 
summed across all relevant food items. Nutrient composition databases which were 
constructed based on U.S. Department of Agriculture (USDA) food composition tables 
(USDA's 1994-96 Continuing Survey of Food Intakes by Individuals [CSFII]) 292. Cut 
points between small and medium portions and between medium and large portions 
corresponded to the 25th and 75th percentiles, respectively, for portion sizes reported by 
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participants in the CSFII, 51 years or older 292. Dietary calcium or dietary vitamin D 
intakes were calculated from all dietary sources, without supplements, respectively. 
 
4.2 Nutrients from supplement use 
Supplement use was calculated from single and/or multi-vitamins based on the 
responses to the supplement questions on the DQX or DHQ. The food frequency 
questionnaire also collected information on multivitamin, single vitamin, and mineral 
supplement use with questions about current use, past use (2 and 5 years ago), dosage, 
and years of intake 293. Values for multivitamins were derived from the third National 
Health and Nutrition Examination Survey (NHANES III) database. Supplemental calcium, 
magnesium, or vitamin D intake were calculated by summing the intake from the single 
vitamin supplement calcium (the specific doses for calcium, dolomite, Tums, and so 
forth.) or vitamin D and multivitamins (162 magnesium calcium and 400 international 
unit (IU) of vitamin D per one-a-day multivitamin pill; 400 IU of vitamin D per therapeutic 
or high-dose types), as defined by the generic multivitamins most frequently reported by 
participants ages 55 to 74 years in the NHANES III cohort 294. In this dissertation project, 
analysis of calcium intake from the supplements is mainly based on current intake (0-2 
years before enrollment). Total calcium and vitamin D intake is defined as dietary plus 
supplemental intake. 
 
5. Screening and diagnostics 
FSG was performed at entry (T0) and then at the 3 (T3) or 5 (T5)-year point. Participants 
randomized before Oct 1994 underwent a second screen at T3. For participants who 
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were randomized between Oct 1994 and Nov 1995, a T3 FSG were scheduled; however, 
T5 FSG were offered if T3 were missed 295. Intervention arm participants randomized 
on/after Dec 1995 were scheduled for FSG at T5. In the intervention arm, 65,000 
subjects underwent baseline FSG and 42,000 received T3 or T5 FSG. There were 
39,000 participants had FSGs both at baseline and at the T3 or T5 FSG. The screening 
results were divided into three mutually exclusive result categories. An FSG was 
defined as “positive FSG” if one or more of the following were found: rectal nodule, 
rectal and/or colon mass, and/or colon polyp. An FSG was defined as “inadequate” if a 
<50-cm depth of insertion was achieved or visual inspection was limited to <90% of the 
mucosal surface due to inadequate bowel preparation. Otherwise, an FSG was defined 
“negative” group if there was no detection of a polyp or mass. Subjects with inadequate 
screening could return for a second examination. Among 7,522 inadequate cases, 632 
returned and 7,099 continued to be defined as inadequate after the second screening.  
 
Participants with a positive screening were referred to their health care providers for 
further diagnostic evaluation and follow-up. Within 12 months after a positive screening, 
the PLCO abstracted medical records pertaining to diagnostics. Information on date of 
diagnosis, the anatomic location, the size and histology of polyps and masses were 
collected. In addition, classifications of malignant tumors (TNM) clinical and pathologic 
stages were abstracted for participants with CRC. 
 
6. Follow-up  
Study centers actively tracked subjects to collect, assemble, organize, and abstract 
medical record information related to diagnosis during the follow-up. Participants would 
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be followed until death or termination of the study (13 years from randomization) to 
ascertain all cancers of the prostate, lung, colorectal, and ovary, as well as deaths from 
all causes. The main sources by which study personnel learned of participants' 
diagnosis/death were (1) abnormal FSG screening, (2) the administration of the Annual 
Study Update (ASU) questionnaires, (3) reports from relatives, friends, or physicians, 
and (4) National Death Index (NDI) plus searches. Study centers also attempted to 
obtain a death certificate for each death that occurred on or before December 31, 2009. 
Information from the death certificate was abstracted and coded in the trial database. 
The underlying cause of death from death certificate was derived according to rules 
established by the National Center for Health Statistics. In order to ensure a more 
accurate assessment of the trial endpoints, a Death Review Process (DRP) was 
conducted and medical records were reviewed for all deaths that might have been due 
to prostate, lung, colorectal and ovarian cancers. The DRP cause of death was 
considered authoritative and will be used in statistical analyses of the primary endpoints. 
 
In addition, cancer incidence, stages, and case survival data were also collected using 
the ASU questionnaire. The ASU was followed by linkage to medical records to confirm 
the diagnosis. The diagnosis of colorectal neoplasia was through medical record 
abstraction (MRA).  
 
7. Outcomes in the PLCO trial 
7.1 Incidence of colorectal adenoma 
Participants (n=22,521) with a negative T0 FSG in the intervention arm of the PLCO trial 
were eligible to be included in the sub-cohort for evaluation of incident colorectal 
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adenoma risk. In addition, an adequate T3/5 screen was required to further classify an 
incident adenoma case or control. Cases must have a positive T3/5 screen which led to 
the discovery of a left-sided adenoma 296. Controls must have a negative T3/5 FSG. 
Filters including a valid BQ (n=22,500), no cancer history before BQ (n=21,693), 
complete DQX (n=19,503), a valid DQX (n=19,088), no cancer history before DQX 
(n=19,076) were further applied. Finally, 1,147 incident colorectal adenoma cases and 
17,929 control participants were identified. An adenoma with ≥1 cm in size, high-grade 
dysplasia, or villous component was defined as an advanced adenoma (Figure 3.1).  
 
7.2 Metachronous colorectal adenoma (recurrent adenoma) 
The Study of Colonoscopy Utilization (SCU) was designed as an ancillary study nested 
within the PLCO trial, which aimed to investigate the utilization of subsequent 
colonoscopy in the PLCO screening arm. Participants with a positive baseline FSG 
screening, diagnostic endoscopy within 6 months from baseline, and no cancer findings 
were invited to complete interviewer-administered telephone-based SCU questionnaire 
296. A baseline adenoma was defined as an adenoma found within the first 18 months 
following a positive T0 FSG screen, on the first endoscopy that followed the screen, or 
on an endoscopy within six months of the first endoscopy following the screen. A 
questionnaire collected information on all known colonoscopy after randomization. 
 
Medical record abstraction was performed to verify the collected questionnaire 
information. Individuals who were diagnosed with an adenoma in the second endoscopy 
were defined as recurrent colorectal adenoma cases. Participants not in SCU but with a  
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Figure 3.1 The flow chart of the population sample size in the PLCO 
 
positive T3/5 screen which resulted in an endoscopy that discovered recurrence were 
also included. 
 
We further restricted the population to those who were diagnosed with adenoma at 
baseline endoscopy, had a second endoscopy, completed a valid BQ (n=1,978), no 
cancer history before BQ (n=1,894), complete DQX (n=1,784), a valid DQX (n=1,742), 
and who had no cancer history before DQX (n=1,741). The final analysis included 855 
colorectal metachronous adenoma cases and 886 controls (Figure 3.1).  
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7.3 Incident CRC  
Medical records related to diagnostic follow-up, a diagnosis of CRC, and cancer 
complications were collected. The intervention arm of the PLCO trial was further 
restricted to a valid BQ (n=75,611), no history of any cancer prior to BQ (n=72,151), 
completed a DQX (n=60,358), has valid DQX (n=58,637), and no history of any cancer 
prior to DQX (n=58,587). The control arm of the PLCO trial was further restricted to a 
valid BQ (n=74,366), no history of any cancer prior to BQ (n=70,885), and no history of 
any cancer prior to DQX (n=49,976). The final analysis included 58,587 subjects in the 
intervention arm, of which 749 were incident CRC cases and 57,838 CRC free controls. 
The control arm was reduced to 49,976 participants with valid BQ, DQX and no cancer 
history, of whom 620 were incident CRC cases and 49,356 were CRC free participants 
(Figure 3.1).   
 
8. Statistical Analysis  
The incidence of colorectal adenoma and metachronous adenoma were only followed 
up within the intervention arm of the PLCO. The information on CRC incidence was 
abstracted within both intervention and control arms. Thus, participants included in this 
study were from both intervention and control arms of the PLCO trial. 
 
8.1 Power analysis  
The main purpose of the project A was to investigate the association between calcium 
intake and the risk of various stages of colorectal neoplasia (incident and metachronous 
adenoma, and incident CRC). Among these three longitudinal outcomes, the number of 
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events is lowest for CRC incidence (n=749). Since the number of events is a major 
determinant of power in the survival analysis, the power analysis was conducted on the 
uses the CRC incidence. We expect power will be larger for other outcomes such as 
incidence and recurrence of adenoma with more events for similar HR’s.   
 
This power analysis was based on the following parameters: 29,288 experimental 
subjects (whose calcium intake is higher than 1135 magnesium per day (median)), 
29,288 control subjects (whose calcium intake is no more than 1135 magnesium per 
day), an accrual interval of 1,095.75 days, and additional follow-up after the accrual 
interval of 4,748 days. An estimated median survival time of the control group is 
230,115.5 days. If the true hazard ratio of control subjects relative to experiment subjects 
is 1.25, we will be able to reject the null hypothesis that the experimental and control 
survival curves are equal with a power of 0.893. The type I error probability associated 
with this test of the null hypothesis is 0.05. The power analysis was done using the PS 
software. Table 3.1 shows the detailed alternatives to this power analysis. 
 
Table 3.1 Study power for main effect of Ca intake in relationship to CRC in Aim 1 
Median survival 
time (days)* 
Hazard Ratio (Relative Risk) 
1.05 1.10 1.15 1.20 1.21 1.22 1.23 1.24 1.25 1.30 
230115.5 0.113 0.294 0.537 0.754 0.788 0.820 0.847 0.872 0.893 0.961 
226463 0.115 0.297 0.543 0.761 0.795 0.826 0.853 0.877 0.898 0.964 
175328 0.134 0.367 0.651 0.857 0.885 0.908 0.927 0.943 0.956 0.989 
138803 0.156 0.444 0.751 0.925 0.944 0.958 0.970 0.978 0.984 0.998 
102270 0.195 0.561 0.865 0.977 0.985 0.990 0.994 0.996 0.998 1.000 
65745 0.274 0.747 0.967 0.998 0.999 1.000 1.000 1.000 1.000 1.000 
29220 0.518 0.972 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 
*: This median survival time for controls is estimated using a formula of t × log(1/2) / log(p); i.e.: t is the 
observed maximal follow-up time of 4,748 days at which p = 0.98864 is the probably that a control subject 
survived. 
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8.2 The list of potential co-variables  
Continuous variables included age at randomization, body mass index (BMI), total 
intakes of calcium, calories, copper, folic acid, iron, magnesium, phosphorous, vitamins 
A, B6, B12, C, D, and E, zinc. Categorical variables contained aspirin use (yes, no), 
cigarette smoking status (never, current cigarette smoker, and former cigarette smoker), 
drinker (yes, no), education (<8 years, 8-11 years, 12 years or completed high school, 
post-high school training other than college, some college, college graduate, and 
postgraduate), family history of CRC (yes, no), race (white, black, Hispanic, Asian, 
pacific islander, American Indian), sex (female, male), vigorous physical activity (none, 
<1, 1, 2, 3, ≥4 h/week). Due to the small count in certain groups, education status was 
reorganized to less than high school, 12 years high school, post-high school or some 
college, and college graduate or more; race was categorized into white, black, Asian 
and others. Other necessary data transformation of variables followed the rule of non-
violation of assumptions of proportional hazards. Potential confounding factors was 
selected based on biological plausibility,  literature reports and ≥10% change in relative 
risks 297.   
 
8.3 Effect modifiers 
It was hypothesized that the association between calcium intake and the risk of 
colorectal neoplasia differs by sex, race and the levels of Ca:Mg ratio, magnesium and 
vitamin D. Thus, these factors were considered as possible effect modifiers. Likelihood 
ratio tests, comparing the differences in log-likelihoods for interaction terms in the full 
model and no interaction terms in the reduced model, were used to assess the 
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significance (<0.05) of interactions. For the outcome of CRC incidence, Wald test was 
conducted to assess interactions.  
 
8.4 Analytical methods 
Summary statistics for both continuous (mean ± standard deviation) and categorical 
variables (count and percent) were used to describe study populations. Chi-square tests 
for categorical variables, t-tests and generalized linear models for continuous variables 
were conducted to evaluate differences in the distribution of potential confounding 
factors between different categories of calcium intake. Person-years for CRC incidence 
were calculated from the date of randomization to the date of the most recently 
completed end point follow-up questionnaire, the date of CRC diagnosis, death, or end 
of follow-up, whichever came first 31.   
 
For incident and metachronous adenoma, the occurrence of disease as a case or 
control rather than time to event was considered; thus, unconditional logistic regression 
models were used to calculate odds ratios (OR) and 95% confidence intervals (95%CIs) 
to estimate the associations after adjusting for covariates. Hazard ratios (HR) and 
95%CIs for incident CRC were estimated using Cox proportional hazard models. 
Potential confounding factors were selected based on biological plausibility, literature 
reports and/or ≥10% change in relative risks 297. Confounding factors evaluated 
included age, sex, race, education, recruitment site, family history of CRC, body mass 
index, smoking status, alcohol consumption, exercise and daily intakes of total energy, 
vitamin D and magnesium. Tests for trend across categories were performed in 
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regression models by assigning the score j to the jth level of the variable selected. An a 
priori stratified analysis by Ca:Mg intake ratio was conducted. For metachronous 
adenoma and CRC incidence in the intervention arm, stratified analyses on baseline 
adenoma characteristics (e.g. advanced and/or synchronous adenoma) and subsites 
were performed. All tests were 2-sided and statistical significance level was set at 0.05. 
Statistical analyses were performed using SAS statistical software (version 9.4; SAS 
Institute, Cary, NC). 
 
B. The Personalized Prevention of CRC Trial (PPCCT, project B&C) 
1. Study Population 
Adenoma and/or hyperplastic polyp cases aged from 40 to 85 years were recruited from 
two major sources: 1) Two existing large adenoma studies (Tennessee Colorectal Polyp 
Study (TCPS) and Tennessee-Indiana Adenoma Recurrence Study (TIARS)) in which 
participants were diagnosed between 2003 to 2010 and agreed to be contacted for 
future studies; and 2) Patients with colorectal adenoma and/or hyperplastic polyp 
diagnosed from 2008 to 2012 at Vanderbilt University Hospital. Participants had a 
calcium intake ≥ 700 mg/day and < 2000 mg/day measured with two 24-hour dietary 
recalls. In addition, the Ca:Mg intake ratio of participants was greater than 2.6. A list of 
exclusion criteria was applied: a history of colectomy, inflammatory bowel disease, any 
organ transplantation, cancer other than non-melanoma skin cancer, gastric bypass, 
chronic renal diseases and hepatic cirrhosis, chronic ischemic heart disease, diarrhea, 
type I diabetes mellitus, pituitary dwarfism; current use of lithium carbonate therapy, 
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blood anticoagulant drugs, digoxin and licorice; without contact information and 
informed consent.  
 
2. Enrollment 
Trained research staff reviewed the medical record of potential participants. If 
participants were eligible, an introductory letter signed by the parent study principal 
investigator and another introductory letter signed by the principal investigator and the 
gastroenterologist described the study and invited them to participate. A few days after 
the letter was mailed, the trained research staff of the Survey Research Shared 
Resource called the potential participant to provide more detailed information about the 
study, answered questions about the study, and to see if they may be interested in 
participating. During the telephone conversation, a series of yes/no screening questions 
were administered to determine eligibility based on the exclusion criteria. If the person 
was eligible, implied verbal consent was obtained to conduct the baseline interview 
survey and 24-hour dietary recalls prior to the first in-person clinic visit (CV#1). For 
eligible participants from Vanderbilt University Hospital and other sources, implied 
verbal consent was obtained to collect a mouthwash sample for genotype assay and 
then to conduct two 24 hour dietary recalls and a baseline interview survey. Eligible 
participants were scheduled for three clinic visits.  
 
3. Randomization and study design 
The project of 2&3 are nested in the parent PPCCT study. The PPCCT is a 2×2 factorial 
design (magnesium treatment and TRPM7 genotype) which enrolled 250 participants, of 
which 239 completely finished the study and 11 subjects finished part of the study 
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before withdrawing. The primary endpoints of the PPCCT were the expression of 
carcinogenesis biomarkers in colorectal mucosa. Within each group of individuals with 
different TRPM7 genotypes (GG vs GA/AA), a permuted-block randomization algorithm 
was used to allocate the subjects into either the treatment or placebo arm. 
 
4. Dietary Ca:Mg intake assessment, intervention and clinic visit 
Two 24-hour dietary recall assessments were used to estimate the baseline Ca:Mg 
intake ratio. The recalls were based on the Minnesota Nutrient Data System (NDS) and 
were administered by the Survey Research Shared Resource. Information on the 
participant’s use of medications, nutritional supplements, and other conditions was 
collected. Based on a participant’s baseline Ca:Mg intake ratio, the participant was 
assigned to a customized dose that would reduce the Ca:Mg intake ratio to less than 
2.6 but above 2.0. Identical-appearing placebos were made to match magnesium 
capsules.  
 
The intervention period was designed to be 12 weeks. Eligible participants were 
scheduled for three clinic visits (week 1, 6 and 12). Before each clinic visit, participants 
received a study package, which included an instruction booklet, a Food Amounts 
booklet, clinic visit questionnaire forms, and diet, health, and probiotics questionnaires. 
Information on the participant’s use of medications, nutritional supplements, and other 
conditions were collected. Rectal biopsy, blood, and urine biospecimens were collected 
and processed in each clinic visit. Anthropometric measurements (blood pressures, 
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weight, height, waist and hip circumstance) were measured at least twice in each clinic 
visit.  
    
5. Biomarkers assay 
As of April, 2014, 150 participants had finished the trial and their samples were assayed 
for a lipid profile and uric acid. Blood was collected from a forearm vein at each clinic 
visit after participants had fasted for at least 8 hours. The blood was clotted and 
immediately centrifuged to separate serum, which was rapidly cooled and frozen at -
80oC before biochemistry analysis. The 150 pairs of pre- and post-treatment serum 
samples of participants who finished the trial were sent to the Vanderbilt Lipid 
Laboratory for assay.  
 
The four lipid biomarkers (LDL-c, HDL-c, total cholesterol, and triglycerides)  as well as 
uric acid were assayed by the Vanderbilt Lipid Laboratory, which is standardized by the 
Centers for Disease Control and Prevention for lipid analysis 298. Total cholesterol, HDL-
c, triglycerides, and uric acid were measured using the Reagents of ACE® Cholesterol 
(#SA1010), HDL-c (#SA1038), triglycerides (#SA1023), and uric acid (#SA1025) 
respectively 298. The detailed assay procedure can be referred to the appropriate Alfa 
Wassermann Diagnostic Technologies, LLC Clinical Chemistry Systems Operator's 
Manual. When triglycerides was less than or equal to 400 mg/dl, the LDL-c was a 
calculated by subtracting HDL-c and one-fifth of triglycerides from the total cholesterol. 
Otherwise, the direct LDL-c was directly measured using the ACE LDL-c Reagent 
(#SA1040) 298. Based on values measured from quality control samples, intra-assay and 
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inter-assay variation coefficients were 1.28% and 4.03% for LDL-c; 0.63% and 2.19% 
for HDL-c; 0.67% and 5.12% for triglycerides; 0.75% and 2.06% for total cholesterol, 
1.72% and 7.64% for uric acid. 
 
6. Statistical power  
The estimate of power is focused on the primary endpoint of LDL-c and uric acid. The 
conservative estimate of power is based on McNemar's test. The paired fourfold table of  
the McNemar’s test was 
presented in Table 3.2. Our 
pilot data shows that 38% at 
baseline had abnormal LDL-c, and after 12 weeks of treatment 25% had abnormal LDL-
c. The same pattern was found for uric acid in the pilot data. One third with abnormal 
LDL-c at baseline lowered their LDL-c to normal range, and none of those with normal 
LDL-c at baseline became abnormal after 12 weeks of treatment. In the biomarker 
assay, we have measured 150 pairs (150 subjects before and after treatment) of serum 
samples. We assumed that the balance of treatment and placebo was 1:1. Thus, we 
had 75 pairs of LDL-c and uric acid measures in the treatment group. With a 0.05 two-
sided significance level, a sample size of 75 will have 95% power to detect a difference 
in proportions of 0.125 (p10 - p01) when the proportion of discordant pairs is expected to 
be 0.135 (p10 + p01). Table 3.3 contains estimated power for McNemar's test of equality 
of paired proportions. We do not expect a significant change of biomarkers in the 
placebo arm, thus we have an equal number (n=75) of subjects in the placebo arm.  
 
Table 3.2 The paired fourfold table of the McNemar's test 
 Post-treatment 
Pre-
treatment 
 Normal Abnormal 
Normal  p00 p01 
Abnormal  p10 p11 
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7. Analytic methods  
The parent PPCCT is still blinded for primary outcomes; thus, an independent 
statistician outside of the study team conducted the statistical analyses for the current 
study. Summary statistics for lipid biomarkers as continuous variables (mean ± standard 
deviation, median, and inter quartile range) was derived for each randomization group. 
The distributions of continuous outcomes were assessed for normality by using the 
Kolmogorov-Smirnov test. Both within-group change and between-group comparisons 
were evaluated. Paired t-test (normal) or the Wilcoxon-signed rank test (non-normal) 
was conducted to evaluate whether pre- and post-treatment values were different within 
each group (treatment or placebo). Either the parametric two-sample t-test or the non-
parametric Wilcoxon Rank Sum test was performed to evaluate between-group 
differences. Generalized linear regression analysis was performed to examine the effect 
of magnesium treatment on lipid profile while adjusting for baseline lipid biomarkers. All 
participants had a baseline Ca:Mg ratio ≥ 2.6. Participants were thus classified into 
three groups based on the concordance between the baseline Ca:Mg ratio and the 
Ca:Mg ratio measured from the FFQ (the median interval to baseline was around 5.0 
years): long-term high ratio (FFQ Ca:Mg ratio ≥ 2.6), recent high ratio (FFQ Ca:Mg ratio 
< 2.6), and unknown ratio (Ca:Mg ratio from the FFQ is unmeasured). Stratified 
analyses were conducted by the categories of the change in the Ca:Mg ratio for both 
long-term and recent high. The statistical significance was 0.05 using two-sided test. 
Table 3.3 Study power for lipid panels (project 2) and uric acid (project 3) in the PPCCT 
 1 2 3 4 5 6 
Test significance level, α 0.050 0.050 0.050 0.050 0.050 0.050 
Difference in proportions,  p10 - p01 0.125 0.115 0.105 0.095 0.085 0.075 
Proportions of discordant pairs, p10 + p01 0.135 0.125 0.115 0.105 0.095 0.085 
Power 0.95 0.92 0.88 0.83 0.75 0.66 
57 
 
The data analysis used software R and SAS® (version 9.4; SAS Institute, Cary, North 
Carolina).  
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Chapter 4. Results 
A. Calcium: magnesium intake ratio and colorectal carcinogenesis, results from 
the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial 
Characteristics of the selected population 
The distribution of selected demographic characteristics and potential confounders in 
cases and controls for incident and metachronous adenoma are shown in Table 4.1. 
Compared to controls, adenoma cases were more likely to be male, smokers, physically 
inactive, and had higher body mass index, higher intake of energy, but lower intakes of 
calcium, magnesium and vitamin D. Compared to participants without metachronous 
adenoma, metachronous adenoma cases were also more likely to be male and obese, 
to have family history of CRC, higher intake of total energy but lower intake of calcium. 
Metachronous adenoma cases were less likely to be white.  
 
The selected basic characteristics in the intervention and control arms for the study of 
incident CRC are compared in Table 4.2. For both intervention and control arms, 
compared to the lower calcium intake (<600mg/day), participants with higher calcium 
intake were less likely to be male, but more likely to be white, never smokers, aspirin 
users, physically active, and had lower BMI, higher education achievement and family 
history of CRC , and higher intakes of energy, magnesium and vitamin D.  
 
Incident colorectal adenoma  
There was no significant association between calcium intake and risk of incident 
colorectal adenoma (Table 4.3). However, compared to the lowest category of calcium 
59 
 
intake, higher intakes of calcium were associated with a suggestive reduced risk of 
advanced and/or synchronous adenoma (P for trend, 0.05). In the stratified analysis 
Ca:Mg ratios, the inverse association between calcium intake and advanced and/or 
synchronous adenoma primarily appeared in participants with Ca:Mg ratios ranging 
from 1.7 to 2.5 (P for trend, 0.05). No significant association was observed when the 
Ca:Mg ratio was above 2.5.  
 
Metachronous (recurrent) adenoma 
We found calcium intake was not related to risk of metachronous adenoma (Table 4.4). 
We also did not find significant associations in the stratified analysis by Ca:Mg intake 
ratio (Table 4.4), location of adenoma (i.e. distal or proximal, data not shown), and 
baseline adenoma characteristics (i.e. advanced/synchronous adenoma) (Supplement 
Table 4.7).This null association was similar for advanced and/or metachronous 
adenoma (Table 4.4). The Ca:Mg ratio stratified analysis showed null results as well.  
 
CRC incidence  
We found calcium intake was significantly related to a reduced risk of CRC (P for trend, 
0.03) (Table 4.5). This significant inverse association was primarily present for distal 
CRC (P for trend, <0.01) but not for proximal colon cancer. In the analysis stratified by 
the Ca:Mg intake ratio, we found the inverse association was only statistically significant 
in participants whose Ca:Mg ratio ranged from 1.7 to 2.5 (P for trend, 0.04). There was 
a significant interaction between calcium intake and the Ca:Mg ratio in relation to distal 
CRC (P for interaction, <0.01).  
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Stratified analysis by treatment  
We found, in the control arm without regular endoscopy, the significant association 
between calcium intake and risk of incident distal CRC remained (P for trend, <0.01, 
Table 4.6) and this inverse association appeared to be primarily in those with Ca:Mg 
intake ratios between 1.7 and 2.5,  although this was not statistically significant. 
However, in the intervention arm with endoscopy screening, the inverse association 
between calcium intake and risk of incident distal CRC was of borderline significance (P 
for trend, 0.06, Table 4.6). In further analysis stratified by feature of the baseline 
adenomas, we found among participants with advanced/synchronous adenoma at 
baseline, higher calcium intake was inversely associated with risk of incident CRC (P for 
trend, 0.04) in the intervention arm (Supplement Table 4.7). Comparable data on were 
not available in the control arm. 
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Table 4.1 Selected descriptive characteristics of adenoma cases and controls 
Characteristics 
Adenoma 
 
Metachronous adenoma  
Cases 
(N=1147) 
Controls 
(N=17929) 
P value 
Cases 
(N=855) 
Controls 
(N=886) 
P value 
Age (years), Mean  SD 62.15.3 62.35.2 0.13  62.94.8 62.75.2 0.41 
Sex, %        
Men 67.5 55.9 <.0001  72.4 60.0 <.0001 
Race, %        
  White 90.6 88.9 0.07  93.0 96.1 0.009 
Education, %        
College or higher  38.7 39.5 0.38  38.0 35.7 0.68 
Smoking status, %        
Never smoker 42.6 53.4   34.5 37.5  
Former smoker 47.3 41.4   52.1 49.3  
Current smoker 10.1 5.2 <.0001  13.4 13.2 0.42 
Alcohol consumption, % 81.1 79.1 0.10  84.0 83.1 0.61 
Family History of CRC , % 10.5 9.1 0.13  13.2 13.7 0.79 
Aspirin use, % 48.4 46.8 0.30  44.7 43.9 0.74 
Physically inactive, % 16.6 12.0 <.0001  15.1 15.2 0.93 
Body mass index≥ 30, % 25.3 21.9 0.003  27.9 23.7 0.02 
Daily nutrients intake, Mean  SE        
Total energy (kcal)1 2187.023.6 2086.56.0 <.0001  2185.527.6 2088.927.1 0.01 
Total calcium (mg)2 1160.515.8 1255.14.0 <.0001  1119.016.6 1196.816.3 0.0008 
Total magnesium (mg) 2 431.63.1 444.40.8 <.0001  431.43.7 439.43.6 0.12 
Vitamin D (mcg/day) 2 10.80.3 12.10.1 <.0001  10.40.3 11.00.3 0.09 
1 Least squares mean value, SE 
2 Least squares mean value, SE, adjusting for total energy 
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Table 4.2 Selected descriptive characteristics of participants by calcium intake (mg/day) 
Characteristics 
Intervention arm 
 
Control arm 
< 600 600-1200 
1200-
1600 
≥1600 P < 600 
600-
1200 
1200-
1600 
≥1600 P 
N 7323 24475 12354 14383   12678 21185 9584 6487  
No. of CRC cases 100 315 128 154   174 242 99 63  
Person-years 80222 273937 138958 161286   142777 241744 110113 74392  
Age (years)            
  Mean1 62.6 62.7 62.6 62.6   62.6 62.5 62.5 62.5  
  SE 0.06 0.03 0.05 0.04 0.12  0.05 0.04 0.05 0.07 <.0001 
Sex (men), % 53.7 58.6 50.2 39.2 <.0001  55.9 52.2 36.1 34.0 <.0001 
Race (white), % 81.3 90.2 93.1 94.7 <.0001  85.2 91.9 93.4 95.7 <.0001 
Education, %            
College or higher  48.5 56.9 59.3 61.1 <.0001  54.0 57.9 59.3 61.1 <.0001 
Smoking status, %            
Never smoker 42.4 44.5 47.9 52.2   44.0 47.1 50.6 51.6  
Former smoker 44.0 44.8 43.3 40.5   44.4 43.9 41.3 40.9  
Current smoker 13.6 10.7 8.8 7.3 <.0001  11.6 9.0 8.1 7.5 <.0001 
Alcohol consumption, % 75.6 78.7 77.8 76.2 <.0001  72.8 73.8 72.5 69.7 <.0001 
Family history of CRC , % 10.3 10.9 10.5 11.0 0.0038  9.9 10.3 10.2 10.4 0.61 
Aspirin use, % 43.0 46.4 49.1 49.3 <.0001  45.2 47.7 47.5 48.5 <.0001 
Body mass index ≥ 30, % 25.1 24.1 24.3 22.7 <.0001  24.5 23.8 21.2 22.3 <.0001 
Total energy (kcal)2            
  Mean1 1340.8 1913.4 2236.7 2477.5   1296.0 1781.0 1867.9 2217.1  
  SE 8.4 4.6 6.5 6.0 <.0001  6.0 4.6 6.9 8.4 <.0001 
Total magnesium (mg)2            
  Mean3  351.4 410.3 454.3 500.7   324.3 364.9 391.1 432.3  
  SE 1.2 0.6 0.9 0.8 <.0001  0.8 0.6 0.9 1.1 <.0001 
Vitamin D (mcg/day)            
  Mean2  4.0 9.1 13.8 19.3   6.6 9.0 10.9 13.8  
  SE 0.09 0.07 0.05 0.07 <.0001  0.05 0.03 0.05 0.06 <.0001 
1 Least squares mean value, SE 
2 Least squares mean value, SE, adjusting for total energy 
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Table 4.3 ORs and 95% CIs1 for colorectal adenoma incidence by 
calcium intake 
Ca Intake 
(mg/day) 
Any adenoma  
Advanced and/or 
synchronous adenoma 
Cases OR (95% CI)  Cases OR (95% CI) 
All 
 <600 139 0.89 (0.72-1.12)  55 1.17 (0.82-1.68) 
 600-1200 545 1.00 (Ref)  192 1.00 (Ref) 
1200-1600 219 0.82 (0.68-0.97)  70 0.71 (0.52-0.96) 
 ≥1600 244 0.84 (0.69-1.03)  83 0.80 (0.58-1.11) 
 P trend2 0.17  0.05 
Ca:Mg ratio is between 1.7 to 2.5 
 <600 64 0.91 (0.66-1.26)  31 1.50 (0.92-2.47) 
 600-1200 284 1.00 (Ref)  93 1.00 (Ref) 
1200-1600 62 0.72 (0.51-1.02)  19 0.60 (0.33-1.08) 
 ≥1600 35 0.91 (0.55-1.51)  11 0.64 (0.27-1.54) 
 P trend2 0.61  0.05 
Ca:Mg ratio is above 2.5 
<600 13 0.86 (0.47-1.60)  2 0.45 (0.11-1.88) 
 600-1200 190 1.00 (Ref)  63 1.00 (Ref) 
1200-1600 154 0.81 (0.64-1.03)  50 0.74 (0.50-1.12) 
 ≥1600 207 0.81 (0.62-1.06)  72 0.77 (0.49-1.22) 
 P trend2 0.16  0.43 
P interaction3 0.94  0.11 
1 Adjusted for age (continuous), sex, BMI (<25, 25-30, ≥30), education 
(less than high school, 12 years or completed high school, post high 
school  training other than college, some college, college graduate, 
postgraduate), race (white, black, asian or others), family history of CRC 
(yes or no), cigarette (never smoked cigarettes, current or former), hours 
spent in vigorous activities (less than1 hour/week, 1 hour/week, 2 
hours/week, 3 hours/week, 4+ hours/week),  and total energy and vitamin 
D intake 
2 Assigned the score j to the jth level of calcium intake and evaluated the 
significance of Wald test 
3 Estimated the full model with interaction term of calcium intake and 
Ca:Mg ratio and without this term in reduce model using likelihood ratio 
test 
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Table 4.4 ORs and 95% CIs1 for metachronous colorectal adenoma 
incidence by calcium intake 
Calcium 
Intake 
(mg/day) 
Any metachronous 
adenoma  
 
Advanced and/or 
metachronous adenoma 
Cases OR (95% CI)  Cases OR (95% CI) 
All 
 <600 124 1.23 (0.87-1.73)  65 1.45 (0.96-2.19) 
 600-1200 393 1.00 (Ref)  198 1.00 (Ref) 
1200-1600 190 1.02 (0.77-1.34)  96 0.97 (0.69-1.38) 
 ≥1600 148 0.83 (0.60-1.15)  81 0.92 (0.61-1.37) 
 P trend2 0.15  0.21 
Ca:Mg ratio is between 1.7 to 2.5 
 <600 63 1.33 (0.82-2.17)  32 1.44 (0.80-2.62) 
 600-1200 194 1.00 (Ref)  91 1.00 (Ref) 
1200-1600 53 0.90 (0.52-1.56)  24 1.03 (0.51-2.07) 
 ≥1600 22 2.34 (0.82-6.68)  11 3.32 (0.95-11.64) 
 P trend2 0.89  0.90 
Ca:Mg ratio is above 2.5 
<600 9 0.85 (0.32-2.27)  4 0.76 (0.22-2.59) 
 600-1200 137 1.00 (Ref)  74 1.00 (Ref) 
1200-1600 133 1.02 (0.69-1.50)  70 0.86 (0.53-1.38) 
 ≥1600 124 0.73 (0.47-1.13)  68 0.65 (0.37-1.13) 
 P trend2 0.21  0.18 
P interaction3 0.53  0.40 
1 Adjusted for age (continuous), sex, BMI (<25, 25-30, ≥30), education 
(less than high school, 12 years or completed high school, post high 
school  training other than college, some college, college graduate, 
postgraduate), race (white, black, asian or others), family history of CRC 
(yes or no), cigarette (never smoked cigarettes, current or former), hours 
spent in vigorous activities (less than1 hour/week, 1 hour/week, 2 
hours/week, 3 hours/week, 4+ hours/week),  and total energy, 
magnesium and vitamin D intake 
2 Assigned the score j to the jth level of calcium intake and evaluated the 
significance of Wald test 
3 Estimated the full model with interaction term of calcium intake and 
Ca:Mg ratio and without this term in reduce model using likelihood ratio 
test 
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Table 4.5 HRs and 95% CIs1 for CRC incidence by calcium intake 
Calcium 
Intake 
(mg/day) 
CRC incidence  Proximal CRC  Distal CRC  
Cases HR (95% CI)  Cases HR (95% CI)  Cases HR (95% CI) 
All  
 <600 274 1.12 (0.95-1.33)  133 0.94 (0.74-1.19)  141 1.38 (1.08-1.76) 
 600-1200 557 1.00 (Ref)  302 1.00 (Ref)  254 1.00 (Ref) 
1200-1600 227 0.85 (0.72-1.01)  134 0.94 (0.75-1.17)  93 0.75 (0.58-0.97) 
 ≥1600 217 0.89 (0.73-1.07)  121 0.97 (0.75-1.26)  92 0.75 (0.56-1.01) 
 P trend2 0.03  0.99  <0.01 
 Ca:Mg ratio is between 1.7 to 2.5 
 <600 101 1.12 (0.85-1.47)  50 0.95 (0.65-1.39)  51 1.34 (0.90-1.99) 
 600-1200 269 1.00 (Ref)  144 1.00 (Ref)  124 1.00 (Ref) 
1200-1600 51 0.70 (0.49-1.01)  28 0.80 (0.48-1.33)  23 0.62 (0.37-1.06) 
 ≥1600 21 0.89 (0.51-1.55)  11 1.19 (0.56-2.54)  9 0.59 (0.25-1.39) 
P trend2 0.17  0.94  0.04 
 Ca:Mg ratio is above 2.5 
 <600 25 1.16 (0.75-1.79)  10 0.78 (0.41-1.51)  15 1.76 (0.98-3.14) 
 600-1200 213 1.00 (Ref)  124 1.00 (Ref)  89 1.00 (Ref) 
1200-1600 174 0.91 (0.73-1.13)  105 0.97 (0.73-1.29)  69 0.83 (0.59-1.17) 
 ≥1600 195 0.93 (0.73-1.20)  109 0.97 (0.70-1.35)  83 0.84 (0.57-1.24) 
P trend2 0.41  0.93  0.12 
P interaction3 0.08  0.64  <0.01 
1 Adjusted for arm, age (continuous), sex, BMI (<25, 25-30, ≥30), education (less than high school, 12 years or 
completed high school, post high school  training other than college, some college, college graduate, 
postgraduate), race (white, black, asian or others), family history of CRC (yes or no), cigarette (never smoked 
cigarettes, current or former), hours spent in vigorous activities (less than1 hour/week, 1 hour/week, 2 hours/week, 
3 hours/week, 4+ hours/week),  and total energy and vitamin D intake 
2 Assigned the score j to the jth level of calcium intake and evaluated the significance of Wald test 
3 Estimated the full model with interaction term of calcium intake and Ca:Mg ratio and without this term in reduce 
model using likelihood ratio test 
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Table 4.6 HRs and 95% CIs1 for CRC incidence by arms 
Calcium 
Intake 
(mg/day) 
Distal CRC  
in the intervention arm 
 
Distal CRC  
in the control arm 
Cases HR (95% CI)  Cases HR (95% CI) 
All 
 <600 52 1.42 (0.97-2.07)  89 1.43 (1.03-1.98) 
 600-1200 135 1.00 (Ref)  119 1.00 (Ref) 
1200-1600 51 0.74 (0.52-1.06)  42 0.78 (0.54-1.13) 
 ≥1600 62 0.85 (0.58-1.25)  30 0.71 (0.45-1.12) 
 P trend 0.06  <0.01 
Ca:Mg ratio is between 1.7 to 2.5 
 <600 26 1.31 (0.77-2.25)  25 1.42 (0.80-2.53) 
 600-1200 71 1.00 (Ref)  53 1.00 (Ref) 
1200-1600 15 0.68 (0.35-1.32)  8 0.58 (0.24-1.41) 
 ≥1600 7 0.71 (0.25-1.99)  2 0.55 (0.11-2.65) 
 P trend 0.19  0.11 
Ca:Mg ratio is above 2.5 
<600 7 1.63 (0.72-3.69)  8 2.03 (0.88-4.65) 
 600-1200 51 1.00 (Ref)  38 1.00 (Ref) 
1200-1600 36 0.74 (0.46-1.18)  33 0.96 (0.58-1.57) 
 ≥1600 55 0.82 (0.49-1.36)  28 0.86 (0.47-1.60) 
 P trend 0.25  0.29 
P interaction 0.03  0.07 
1 Adjusted for age (continuous), sex, BMI (<25, 25-30, ≥30), education 
(less than high school, 12 years or completed high school, post high 
school  training other than college, some college, college graduate, 
postgraduate), race (white, black, asian or others), family history of CRC 
(yes or no), cigarette (never smoked cigarettes, current or former), and 
total energy and vitamin D intake 
2 Assigned the score j to the jth level of calcium intake and evaluated the 
significance of Wald test 
3 Estimated interaction term of calcium intake and Ca:Mg ratio in Wald 
test 
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Supplemental Table 4.7 ORs1 and 95% CIs for additional outcomes by calcium 
intake 
Ca Intake 
(mg/day) 
Metachronous adenoma  CRC in intervention arm 
Cases OR (95% CI)  Cases HR (95% CI) 
No advanced/synchronous adenoma at baseline 
<600 37 1.92 (1.02-3.59)  73 0.98 (0.74-1.30) 
600 -1200 98 1.00 (Ref)  245 1.00 (Ref) 
1200 -1600 46 0.97 (0.57-1.66)  107 0.86 (0.67-1.10) 
≥1600 41 0.97 (0.52-1.81)  133 0.99 (0.76-1.28) 
P trend2 0.26  0.80 
Has advanced/synchronous adenoma at baseline 
<600 87 1.03 (0.70-1.52)  21 1.46 (0.83-2.59) 
600 -1200 295 1.00 (Ref)  51 1.00 (Ref) 
1200 -1600 144 1.01 (0.73-1.40)  14 0.52 (0.26-1.00) 
≥1600 107 0.78 (0.54-1.14)  17 0.66 (0.34-1.30) 
P trend2 0.28  0.04 
P interaction3 0.553  0.094 
1 Adjusted for age (continuous), sex, BMI (<25, 25-30, ≥30), education (less 
than high school, 12 years or completed high school, post high school  training 
other than college, some college, college graduate, postgraduate), race (white, 
black, asian or others), family history of CRC (yes or no), cigarette (never 
smoked cigarettes, current or former), hours spent in vigorous activities (less 
than1 hour/week, 1 hour/week, 2 hours/week, 3 hours/week, 4+ hours/week),  
and total energy and vitamin D intake 
2 Assigned the score j to the jth level of calcium intake and evaluated the 
significance of Wald test 
3 Estimated the full model with interaction term of calcium intake and Ca:Mg 
ratio and without this term in reduce model using likelihood ratio test 
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B. Ca:Mg Ratio and lipid profile, a randomized clinical trial 
The participants from the magnesium supplementation arm did not significantly differ 
from those from the placebo arm on age, sex, body mass index, smoking, drinking, 
physical activity, education, anti-hypertensive and oral hypoglycemic medication use. A 
higher percentage of participants used lipid-modulating drugs in the placebo arm 
compared to the magnesium treatment arm (Table 4.8). The Kolmogorov-Smirnov test 
showed that the distribution of four lipid biomarkers was not normal (data not shown).  
 
We found magnesium treatment did not significantly affect the lipid profile, including 
LDL-c, HDL-c, triglycerides, and total cholesterol (Table 4.9).  Further, compared to the 
placebo arm, the treatment arm also did not significantly affect lipid profile. We further 
conducted analysis among participants with long-term high Ca:Mg ratios measured by 
two 24-hour dietary recalls and the previously administered FFQ (Table 4.10). We 
found magnesium treatment led to a significant increase of HDL-c level by 5 mg/dl (P 
value, <0.001), but no changes were found for LDL-c, triglycerides, and total cholesterol 
within the magnesium treatment group. In the placebo arm, LDL-c significantly 
decreased (P value, 0.044). Compared to the placebo arm, magnesium treatment 
significantly increased HDL-c (P value, 0.004) and total cholesterol (P value, 0.017) 
even after controlling for controlling for baseline lipid profile. After Bonferroni multiple 
comparison correction, only the effect on HDL-c remained statistically significant.  
 
Finally, we conducted analysis among participants with recent high Ca:Mg ratio 
measures (i.e. >2.6 from two 24-hour dietary recalls, but <2.6 from FFQ conducted 
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earlier) (Table 4.11). We found within the magnesium treatment arm, magnesium 
treatment significantly reduced HDL-c by 3 mg/dl (P value, 0.025), but not others. In the 
placebo arm, levels of triglycerides significantly reduced (P value, 0.043). Compared to 
the placebo arm, magnesium treatment reduced HDL-c (P value, 0.099), but increased 
triglycerides (P value, 0.054) at borderline significance. After adjusting for baseline lipid 
profile, the effect on HDL-c still remained of borderline significance (P value, 0.055), 
although the significance disappeared after Bonferroni correction.   
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Table 4.8 Descriptive characteristics of the included population   
 Magnesium  
(N=76) 
Placebo  
(N=74) 
P value 
Age  60.4±8.2 62.0±7.8 0.3031 
Sex - male (%) 47 (62%) 41 (55%) 0.4232 
Body mass index (BMI) 29.5±6.2 29.9±6.1 0.5331 
Waist to hip ratio  0.97±0.06 0.97±0.05 0.51 
TRPM 7 Genotype - GG (%) 61 (80%) 56 (76%) 0.5192 
Smoking status (%)   0.2932 
  Never  35 (47%) 44 (59%)  
  Ever 33 (44%) 25 (34%)  
  Current  7 (9%) 5 (7%)  
Drinking status (%)   0.0782 
  Never  21 (28%) 32 (43%)  
  Ever 20 (26%) 11 (15%)  
  Current  35 (46%) 31 (42%)  
Physically active in ≥ 2 days per week (%) 57 (75%) 60 (81%) 0.3692 
Education under college (%) 7 (9%) 8 (11%) 0.7442 
Lipid-modulating medication use - yes (%) 18 (24%) 32 (43%) 0.0112 
Oral hypoglycemic drug use - yes (%) 3 (4%) 6 (8%) 0.2832 
Anti-hypertensive drug use - yes (%) 33 (43%) 35 (47%) 0.6342 
Ca:Mg ratio measured by FFQ   0.8132 
  High (≥2.6) 35 (46%) 33 (45%)  
  Low (<2.6) 21 (28%) 18 (24%)  
  Not available 20 (26%) 23 (31%)  
Baseline Ca:Mg ratio 3.5 (3.0-4.0) 3.6 (3.0-4.1) 0.8751 
For continuous variables: X±SD,  median (the lower quartile-the upper quartile) 
Tests used:1Wilcoxon test; 2Pearson test 
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Table 4.9 Within and between group comparison for lipid biomarkers among all participants 
 N 
Magnesium 
(N=76) 
 
Placebo 
(N=74) 
 
Between 
group  
Week 0 Week 12 Differences P1  Week 0 Week 12 Differences P1  P2 P3 
LDL-c 150 
115 (95-153) 117 (92-150) -5 (-15-10.2) 0.320  118 (94-140) 108 (88-142) -4.5 (-17.2-13.5) 0.197  0.73 0.58 
126±51 124±45 -1.8±23.6   120±37 117±40 -2.7±28     
HDL-c 150 
54 (44-71) 56 (44-72) 1.5 (-4-6) 0.403  56 (47-73) 55 (46-71) -1 (-5-5) 0.627  0.38 0.53 
62±27 62±24 0.1±10.1   61±20 60±19 -0.7±9.2     
TG 150 
113 (82-168) 114 (83-164) 5 (-17-42.8) 0.238  119 (77-156) 110 (79-157) -3.5 (-28.8-15.3) 0.575  0.23 0.38 
135±81 142±96 6.6±57.4   133±75 133±78 -0.9±50.3     
TC 150 
199 (164-255) 201 (168-250) 0.5 (-14.8-16) 0.943  199 (173-234) 196 (169-228) -5.5 (-18.8-16.3) 0.278  0.40 0.37 
214±73 213±62 -0.9±33   207±50 203±52 -4.0±37.2     
a (b-c) represent the median a, the lower quartile b, and the upper quartile c for continuous variables     
x ± s represents X¯ ±SD 
LDL-c: low-density lipoprotein cholesterol, HDL-c: high-density lipoprotein cholesterol, TG: triglycerides, TC: total cholesterol 
N is the number of non-missing values 
P1: the P value for within group differences using Wilcoxon signed rank test 
P2: the P value for between group differences using Wilcoxon rank-sum test 
P3: the P value for between group comparison while adjusting for baseline level for each biomarker in the generalized linear model   
 
  
72 
 
Table 4.10 Within and between group comparison for lipid biomarkers among long-term high ratio participants 
 N 
Magnesium 
(N=35) 
 
Placebo 
(N=33) 
 
Between 
group  
Week 0 Week 12 Differences P1  Week 0 Week 12 Differences P1  P2 P3 
LDL-c 68 
108 (86-140) 112 (90-139) 1 (-12-21) 0.473  120 (87-135) 104 (86-128) -11 (-23-8) 0.044  0.035 0.066 
112±48 115±41 2.5±27.3   117±37 108±35 -8.8±21.8     
HDL-c 68 
53 (43-63) 56 (43-69) 5 (-0.5-8.5) <0.001  49 (47-60) 50 (46-59) -2 (-5-5) 0.555  0.004 0.004 
54±19 58±20 4.4±6.7   54±12 53±12 -0.8±7.6     
TG 68 
107 (68-192) 114 (84-154) 8 (-12.5-39) 0.207  124 (84-162) 100 (77-201) -5 (-33-16) 0.668  0.270 0.569 
142±99 151±118 9±59.8   143±83 144±91 0.7±58.1     
TC 68 
181 (152-236) 190 (165-244) 10 (-7.5-28) 0.118  195 (172-216) 186 (165-206) -12 (-37-10) 0.072  0.019 0.017 
195±67 202±55 7.5±33.1   200±49 189±45 -10.2±30.7     
a (b-c) represent the median a, the lower quartile b, and the upper quartile c for continuous variables     
x ± s represents X¯ ±SD 
LDL-c: low-density lipoprotein cholesterol, HDL-c: high-density lipoprotein cholesterol, TG: triglycerides, TC: total cholesterol 
N is the number of non-missing values 
P1: the P value for within group differences using Wilcoxon signed rank test 
P2: the P value for between group differences using Wilcoxon rank-sum test 
P3: the P value for between group comparison while adjusting for baseline level for each biomarker in the generalized linear model   
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Table 4.11 Within and between group comparison for lipid biomarkers among recent high ratio participants 
 N 
Magnesium 
(N=21) 
 
Placebo 
(N=19) 
 
Between 
group  
Week 0 Week 12 Differences P1  Week 0 Week 12 Differences P1  P2 P3 
LDL-c 39 
110 (96-131) 107 (85-133) -7 (-11-5) 0.244  110 (88-137) 102 (81-139) -4.5 (-10.5-3) 0.246  0.98 0.675 
112±32 110±32 -1.9±17.2   114±39 110±38 -4.4±16.6     
HDL-c 39 
52 (44-64) 50 (44-60) -3 (-6-2) 0.025  48 (44-64) 50 (42-70) -1 (-3.5-5.8) 0.861  0.099 0.055 
55±14 53±12 -2.7±4.8   56±17 57±19 1.3±7.7     
TG 39 
110 (81-154) 116 (77-163) 5 (-8-45) 0.444  131 (98-149) 109 (77-122) -13.5 (-39.5-2.2) 0.043  0.054 0.115 
116±50 122±58 6±43.5   132±52 111±48 -20.3±43.1     
TC 39 
188 (162-227) 184 (164-217) 0 (-14-8) 0.432  195 (169-217) 188(157-211) -4.5 (-17-2) 0.133  0.47 0.685 
190±42 187±39 -3.3±19   196±47 189±44 -7.2±24.8     
a (b-c) represent the median a, the lower quartile b, and the upper quartile c for continuous variables     
x ± s represents X¯ ±1SD 
LDL-c: low-density lipoprotein cholesterol, HDL-c: high-density lipoprotein cholesterol, TG: triglycerides, TC: total cholesterol 
N is the number of non-missing values 
P1: the P value for within group differences using Wilcoxon signed rank test 
P2: the P value for between group differences using Wilcoxon rank-sum test 
P3: the P value for between group comparison while adjusting for baseline level for each biomarker in the generalized linear model   
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C. Ca:Mg ratio and uric acid, a randomized clinical trial 
Overall, no significant difference in the change of uric acid from baseline to week 12 
was observed in the magnesium treatment arm (Table 4.12). Among subjects with a 
long-term high Ca:Mg ratio, uric acid was lowered by 0.4 mg/dl within the placebo arm 
(P value, 0.011), which further resulted in a significant difference between magnesium 
treatment arm and placebo arm (P value, 0.026). However, this reduction is not 
significant after we adjusted for baseline uric acid (P value, 0.057).
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Table 4.12 Within and between group comparison for uric acid levels 
Magnesium  Placebo  
Between 
group 
N Week 0 Week 12 Differences P1  N Week 0 Week 12 Differences P1  P2 P3 
All participants 
76 
6.1 (4.6-6.5) 5.8 (4.9-6.8) 0 (-0.6-0.5) 0.886  
74 
5.9 (4.9-7.1) 5.7 (4.9-6.8) -0.1 (-0.8-0.5) 0.29  0.44 0.457 
6.0±1.6 6.0±1.6 0±0.9   6.2±1.6 6.0±1.6 -0.1±1.0     
  Long-term high ratio participants 
35 
5.5 (4.3-6.4) 5.5 (4.7-6.5) 0.1 (-0.6-0.6) 0.568  
33 
5.8 (4.8-7.3) 5.7 (4.9-6.2) -0.4 (-1.0-0.2) 0.011  0.026 0.057 
5.5±1.3 5.6±1.4 0.1±0.9   6.1±1.5 5.7±1.4 -0.4±0.8     
  Recent high ratio participants 
21 
6.3 (5.1-6.5) 6.0 (4.8-6.8) 0 (-0.4-0.3) 0.711  
18 
6.0 (5.0-6.7) 5.5 (4.8-6.6) -0.1 (-0.4-0.5) 0.896  0.99 0.739 
6.1±1.3 6.0±1.4 -0.1± 0.7   6.1±2.0 5.9±1.5 -0.2±1.2     
a (b-c) represent the median a, the lower quartile b, and the upper quartile c for continuous variables   
x ± s represents X¯ ±SD 
N is the number of non-missing values 
P1: the P value for within group differences using Wilcoxon signed rank test 
P2: the P value for between group differences using Wilcoxon rank-sum test 
P3: the P value for between group comparison while adjusting for baseline level for each biomarker in the generalized linear model   
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Chapter 5. Discussion and summary 
A. Project A-discussion 
In the current study, we found higher intakes of calcium, compared to low calcium intake 
(<600 magnesium/day), were not related to a reduced risk of incident adenoma, but 
were associated with a suggestive reduced risk for advanced/synchronous adenomas. 
The inverse association primarily appeared in subjects with Ca:Mg intake ratios 
between 1.7 and 2.5.  Although calcium intake was not related to risk of metachronous 
adenoma regardless of initial adenoma characteristic and Ca:Mg intake ratio, we found 
higher intakes of calcium were associated with a reduced risk of incident distal CRC. 
Further, the inverse association with incident distal CRC was also primarily present in 
those with Ca:Mg intake ratios ranging from 1.7 to 2.5. Moreover, we found the inverse 
association was only significant among control arm without regular endoscopy, and 
became weaker in the intervention arm with regular endoscopy. We found the inverse 
association was only significant for those with baseline advanced/synchronous 
adenomas. To our knowledge, this is the first study to examine whether regular 
endoscopy use modifies the association between calcium and incident CRC risk.  
 
Both cohort studies and earlier intervention trials relatively consistently found high 
calcium intake or calcium supplementation was related to moderately reduced risks of 
adenoma, metachronous adenoma and CRC 18–20,22,23,25,299,300. However, results from a 
very recent large-scale randomized clinical trial (WHI) do not support an effect of 
calcium plus vitamin D supplementation on the incidence of CRC after 7 years of follow-
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up 15. Very recently, Baron et al reported from a large scale randomized trial that 
calcium supplementation did not reduce risk of colorectal metachronous adenoma 16. 
 
It is possible the follow-up time in the WHI was not sufficiently long to observe an effect. 
CRC is believed to arise, in the overwhelming majority of cases, from adenomas via the 
well-established adenoma-carcinoma sequence 301. Our findings from the current study 
may provide possible explanations for the inconsistent results 125,126 in the previous 
studies on the effect of calcium on the colorectal carcinogenesis 17–20. Earlier studies 
hypothesized that the chemoprevention effect of calcium intake on CRC may primarily 
exert in its early stages (adenoma) 15. Our findings are consistent with previous 
epidemiologic data 21,22 indicating higher calcium intake may only inhibit early colorectal 
carcinogenesis at the stage of incident adenoma 17–20,300 and the association may be 
stronger for prevention of advanced adenoma, a premalignant lesion for CRC 4, than 
other types of adenoma or polyps 302.  The possibility is consistent with the observation 
that the magnitude of reduction in overall CRC risk associated with high calcium intake 
is similar to the reduction in adenoma risk.  
 
We did not find calcium intake was related to risk of metachronous colorectal adenoma 
in the current study. However, the sample size, and thus statistical power, is smaller for 
this outcome than for the analyses of incident adenoma and incident cancer. Although 
earlier randomized trials found calcium supplementation reduced risk of colorectal 
metachronous adenoma 23, a recent trial did not find calcium supplementation reduced 
risk of metachronous colorectal adenoma 16. As such, other underlying factors may 
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account for the inconsistency between these randomized trials such as the change of 
the Ca:Mg intake ratio over the time. The Ca:Mg intake ratio has increased from about 
2.6 303 during the period the earlier  trials 23,299 were conducted to over 3 when the 
recent randomized trial was conducted 16. 
 
We found in the current study that the Ca:Mg intake ratio modifies the association 
between calcium intake and development of adenoma and CRC . We also found the 
significant inverse associations between calcium intake and advanced/synchronous 
adenomas, or distal CRC may primarily appear in those with Ca:Mg intake ratios 
between 1.7 and 2.5. We reported earlier that the dietary intake ratio of Ca:Mg modified 
the association between intakes of calcium and magnesium in relation to prevalent 
colorectal adenoma 154. In a subsequent randomized clinical trial, calcium 
supplementation only reduced risk of metachronous colorectal adenoma when the 
baseline Ca:Mg was below 2.63 26. Very recently, we found that Ca:Mg ratio modified 
the associations between intakes of calcium and magnesium and risk of esophageal 
neoplasia 27. Consistent with our finding, one case-control study conducted in Belgians 
reported that a high calcium intake with a low magnesium intake was associated with 
increased risk of bladder cancer 144. In studies conducted in East Asian populations with 
a low Ca:Mg intake ratio (a median around 1.7), we found the association between 
intakes of calcium and magnesium with the risk of total, cardiovascular and/or cancer 
mortalities were modified by Ca:Mg ratio, but not by calcium or magnesium intake alone 
28.  Thus, the balance between calcium and magnesium intake is an important factor to 
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consider in the investigation of associations between intakes of calcium and magnesium 
and cancer development.   
 
In addition to the Ca:Mg intake ratio, we found the inverse association between calcium 
intake and risk of incident distal CRC was stronger in the control arm compared to the 
intervention arm with multiple flexible sigmoidoscopies. These findings suggested the 
association between calcium intake and colorectal carcinogenesis may be attenuated 
by endoscopy screening and the removal of polyps with an endoscopy, which is the 
most effective prevention strategy to reduce the morbidity and mortality of CRC 29.  
 
The protective association with higher calcium intake was mainly in distal CRC, with 
approximately 30-50% reduced risk. This finding is consistent with a meta-analysis of 17 
cohort studies, in which the protective effect of calcium intake was more evident for 
distal colon cancer compared with proximal colon tumors (33% vs 25% of risk reduction) 
12. Previous etiologic studies indicated proximal and distal sections differ in physiological 
functions, fecal composition and transit, as well as suggested that environmental factors 
such as diet mainly affect distal colon carcinogenesis 304.   
 
No previous study has prospectively evaluated the associations of calcium intake with 
incident adenoma, metachronous adenoma, and incident cancer in the same cohort 
using the same food frequency questionnaire, which minimizes misclassification that 
can occur when combining dietary estimates from multiple studies with different food 
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frequency questionnaire instruments. The PLCO screening trial provides a unique and 
unparalleled opportunity to prospectively and concurrently evaluate these associations. 
One weakness is that the PLCO is a sigmoidoscopy-based randomized trial, which only 
screened distal colorectum. Thus, incident adenoma cases mainly included adenomas 
from the left side of the bowel although metachronous adenoma and incident CRC 
cases included cases from both proximal and distal colorectum. However, it is 
interesting that recent reports found that colonoscopy was linked to reduced deaths 
from distal colorectum, but not the right 30,32 while similarly a recent report from the 
PLCO observed sigmoidoscopic screenings only reduced distal, but not proximal CRC 
mortality 31. Further, sigmoidoscopic screenings also significantly reduced both distal 
and proximal CRC incidence in the PLCO 31. Thus, the PLCO provides a unique 
opportunity to test whether calcium intake confers additional protection against proximal 
and distal CRC among those receiving sigmoidoscopic screening(s). Similar to other 
nutritional epidemiological studies using food frequency questionnaire, there are 
possibly non-differential measurement errors which may bias the results to the null. 
 
In conclusion, higher calcium intake may primarily be related to reduced risks of incident 
advanced/synchronous adenoma and incident distal CRC among subjects with Ca:Mg 
intake ratios between 1.7 and 2.5, or participants without regular endoscopy and those 
with advanced/multiple adenomas at baseline. 
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B. Project B-discussion 
In this study, we found overall magnesium supplementation did not affect lipid profile. 
However, among individuals whose Ca:Mg intake ratios were consistently higher than 
2.6, reducing the Ca:Mg ratio through magnesium treatment significantly led to a 
beneficial effect on HDL-c (i.e. an increase by 5 mg/dl). This change remained 
significant after adjusting for baseline HDL-c and multiple comparisons. Conversely, 
among subjects with a Ca:Mg intake ratio which varied over time (i.e. <2.6 from FFQ, 
but >2.6 in two 24-hour dietary recalls), reducing the Ca:Mg ratio through magnesium 
treatment may have reduced HDL-c, although the change was not significant after 
correcting for multiple comparison.  
 
Although not consistent 315,316, earlier clinical trials indicated an increase of HDL-c by 3 
to 4 mg/dl with oral magnesium supplementation among diabetic patients 311. Similarly, 
a more recent meta-analysis of clinical trials among participants with diabetes found 
magnesium significantly increased HDL-c by around 3 mg/dl, and had no effect on LDL-
c, triglycerides, and total cholesterol 212. Consistent with these studies, our results also 
suggested null effects of magnesium treatment on LDL-c, triglycerides, and total 
cholesterol, although previous clinical trials 310,311 generated inconsistent results. These 
findings are biologically plausible since both patients with type 2 diabetes 312 and 
individuals with high Ca:Mg intakes ratio (i.e. ratios >2.6) 17,26,27 are at high risk of 
magnesium deficiency. On the other hand, we previously found among those with very 
low Ca:Mg intake ratios (i.e. ratio<1.7), high intakes of magnesium were related to an 
increased risk of total mortality or mortality due to cardiovascular disease 28. This may 
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explain in our study further reducing the Ca:Mg ratio via magnesium supplementation 
may even decrease HDL-c among those with inconsistent ratios measured by FFQ (i.e. 
ratio<2.6). 
 
It is possible that previous trials of magnesium supplementation enrolled subjects with 
both high and low Ca:Mg ratios; the high doses of magnesium treatment generally used 
in these trials may have led to a very low Ca:Mg ratio (<1.7), particularly for those with a 
low ratio at baseline 212. The modifying effect of the Ca:Mg ratio may explain the 
inconsistent results in previous clinical trials of magnesium supplementations. Likewise, 
the findings for dietary    and supplement calcium 232,233 in relation to cardiovascular 
disease have also been inconsistent. It is likely that dietary sources of calcium are 
usually accompanied by high dietary magnesium intake, and this, in turn, leads to a 
moderate Ca:Mg ratio from dietary sources. In contrast, calcium supplementation alone 
substantially increases the Ca:Mg ratio. This may explain the differential effects of 
calcium from dietary 234,235 and supplemental sources 232,233 on cardiovascular disease 
risk and mortality. Some recent randomized trials found high calcium supplementation 
led to increased risk of myocardial infarction 308. Therefore, instead of considering 
absolute calcium and magnesium alone, the Ca:Mg ratio is another critical factor in lipid 
metabolism as well as other physiologic activities. 
 
The body’s calcium and magnesium status is an integrated function of oral intake, 
intestinal absorption, renal reabsorption and skeletal remodeling 101. Calcium and 
magnesium have common food sources and are considered to be “metabolically 
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interactive” as well 141. Calcium and magnesium may share the same homeostatic 
regulation system 45 primarily through absorption in the intestine and reabsorption in the 
kidneys to maintain the balance of Ca:Mg 45,46.  Nevertheless, calcium and magnesium 
compete with each other in (re)absorption and transport 47–51. A high calcium intake 
reduces absorption of both magnesium and calcium 145 whereas moderate magnesium 
deprivation results in negative magnesium balance but increased calcium retention 146. 
In addition, magnesium supplementation increased urinary calcium excretion if calcium 
intake was less than 800 mg/day 148, suggesting that magnesium may suppress calcium 
reabsorption when Ca:Mg intake ratio is very low 28. Therefore, the Ca:Mg intake ratio 
may have an important role in regulating calcium and magnesium (re)absorption. A high 
Ca:Mg intake ratio implies relatively high calcium but low magnesium intake; thus, 
magnesium supplementation is essential for lowering the already-high calcium status 
among participants with a high Ca:Mg ratio. 
 
Although potential mechanisms of magnesium deficiency on the development of 
cardiovascular disease is not completely understood, animal studies have suggested 
that magnesium intake is highly related to atherogenic process 317.  Specifically, 
magnesium affects apolipoproteins and enzymes involved in lipid metabolism 317. The 
enzyme activity of lecithin cholesterol acyltransferase (LCAT) 240, lipoprotein lipase (LPL) 
202, and 2-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase 244, requires 
the involvement of magnesium 241. In the pathway of cholesterol biosynthesis, HMG-
CoA reductase is a rate-limiting enzyme to transform HMG-CoA to mevalonate 244. This 
conversion process could be affected by statins and regulated by magnesium 244. 
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Magnesium supplementation among participants with a long-term high Ca:Mg ratio may 
their improve magnesium deficiency or insufficiency and subsequently change the 
overall cholesterol biosynthesis process. Therefore, we observed a significant increase 
of HDL-c.  
 
Participants in this study are otherwise healthy volunteers with previous diagnoses of 
hyperplastic polyps or colorectal adenomas, which is different from those reported in 
previous studies 318–320. The baseline levels of lipid profile for the participants are close 
to the normal range. In this study, the average of HDL-c is around 55 mg/dl and LDL-c 
is around 115 mg/dl. Thus, a 5 mg/dl increase in HDL-c may be more beneficial than a 
decrease in LDL-c among this group of participants, which has very significant 
implications for the prevention of cardiovascular disease. It is possible that the 
“regression to the mean” effect exists. Thus, we further adjusted for baseline level of 
lipid profile in final models. Serum calcium and magnesium is strictly regulated by the 
homeostasis system 231. Thus, serum calcium and magnesium are not sensitive 
markers of total body calcium and magnesium status. In our study, dietary intake and 
supplemental use of calcium and magnesium were used as a surrogate of total body 
calcium and magnesium status. However, these measurements have not taken into 
account gastrointestinal absorption.  
 
In conclusion, reducing the high Ca:Mg ratio through magnesium supplementation may 
increase HDL-c in participants with long-term high Ca:Mg intake ratios, but may have a 
detrimental effect among subjects with Ca:Mg ratios <2.6 or not remaining stable. If this 
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finding is confirmed, it provides a novel and inexpensive approach for the prevention of 
cardiovascular disease. 
 
C. Project C-discussion 
In this randomized trial, reducing Ca:Mg ratios through magnesium supplementation did 
not affect concentrations of serum uric acid. Previously, we found the Ca:Mg intake ratio 
modified the associations between intakes of calcium and magnesium and risk of 
gastrointestinal neoplasia 17,26,27, total, cardiovascular disease  and cancer mortalities 28. 
No previous studies have investigated the effect of the Ca:Mg ratio on uric acid. To our 
knowledge, this is the first clinical trial to investigate whether reducing the Ca:Mg intake 
ratio through magnesium supplementation affected uric acid. Our findings indicated the 
Ca:Mg ratio may not affect risk of cancer or cardiovascular disease by modifying uric 
acid. Two previous studies found that magnesium status was correlated with uric acid 
status 275,322. However, these are cross-sectional studies which are difficult to determine 
their temporal relationships. It is possible that uric acid is correlated with lipid profiles, 
inflammation biomarkers and other pathways. Future studies should evaluate whether 
the Ca:Mg ratio may affect pathways such as lipid profiles 323 as well as inflammatory 
responses 324,325. We also cannot exclude the possibility that the null result in the 
current study is due to a small sample size so future larger studies may be needed. 
 
D. Summary, conclusions and future directions  
CRC, a worldwide health burden, is the 3rd most common incident cancer and the 3rd 
leading cause of cancer death in the United States 55. A few modifiable risk factors were 
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associated with colorectal carcinogenesis. Although it is inconsistent, good behavioral 
factors which seem to decrease risk include being physically active, eating healthy, 
keeping an optimal body mass index (18.5 to 25), abstinence from smoking, no to light 
alcohol consumption, hormonal replacement therapy for postmenopausal women, 
regular endoscopy screening to remove polyps, aspirin 326,327 and other non-steroidal 
anti-inflammatory drugs 88 would potentially prevent against CRC 67.  
 
Calcium, a chemopreventive nutrient, was suggested to reduce the risk of incident 
adenoma 17–20, metachronous adenoma 23–25 and cancer 21,22. The Ca:Mg intake ratio 
was suggested to modify the associations between intakes of calcium and magnesium 
and risk of gastrointestinal neoplasia 17,26,27, and total, cardiovascular disease and 
cancer mortalities 28. Previous studies also indicated that a ratio between 1.7 and 2.6 is 
potentially the range needed for calcium intake to be protective against these outcomes 
17,26–28. It is plausible that calcium intake and the Ca:Mg intake ratio play an essential 
role in the development of CRC .  
 
We evaluated the associations between calcium intake and the risks of incident 
colorectal adenoma (1,147 cases), metachronous adenoma (855 cases) and incident 
CRC (697 and 578 cases in intervention and control arms, respectively) among 108,563 
PLCO participants aged 55 to 74 years. Compared to low calcium intake (<600 mg/day), 
higher intakes of calcium were not related to a reduced risk of incident or metachronous 
colorectal adenoma, but were related to a suggestive reduced risk of advanced and/or 
synchronous adenomas and to a significantly reduced risk of CRC, especially for distal 
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CRC. The inverse association was primarily apparent in participants whose Ca:Mg 
ratios ranged from 1.7 to 2.5. In addition, the statistically significant association between 
calcium intake and risk of incident distal CRC appeared to be primarily present in the 
control arm without regular endoscopy. 
 
The 150 pairs of pre- and post-treatment serum samples of participants in the PPCCT 
study who finished the trial were sent to the Vanderbilt Lipid Laboratory assaying of lipid 
panel and uric acid. Overall, magnesium treatment did not significantly affect the levels 
of the lipid profile including LDL-c, HDL-c, triglycerides, and total cholesterol. Among 
participants with a long-term high Ca:Mg ratio, magnesium supplementation led to a 
statically significant increase of HDL-c level by 5 mg/dl. No significant difference in the 
change of uric acid from baseline to week 12 was observed in the magnesium treatment 
arm. 
 
This dissertation suggests higher calcium intake may primarily be related to reduced 
risks of incident advanced and/or synchronous adenoma as well as incident distal CRC 
among subjects with Ca:Mg intake ratios between 1.7 and 2.5, or participants without 
regular endoscopy and those with advanced and/or synchronous adenomas at baseline. 
Thus, this study adds additional evidence to understand associations between calcium 
intake and risk of CRC development at various stages. Previous studies suggested that 
the association between intakes of calcium and magnesium with the risk of total, 
cardiovascular and/or cancer mortalities were modified by Ca:Mg ratio, but not by 
calcium or magnesium intake alone 28. In this study, the potential modifying effect of 
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Ca:Mg intake ratios was further suggested. It is possible that lack of considering Ca:Mg 
balance may explain some of the inconsistency in previous studies on either calcium or 
magnesium intake. Moreover, the association between calcium intake and risk of CRC 
appears to be stronger in individuals without endoscopic screenings. To our best 
knowledge, this is the first study to examine whether regular endoscopy use modifies 
the association between calcium intake and incident CRC risk.  
 
Recent studies indicate that Ca:Mg intake ratio may modify the associations between 
intakes of calcium and magnesium and risk of gastrointestinal neoplasia 17,26,27, and 
total, cardiovascular disease and cancer mortalities 28. This study found that reducing a  
high Ca:Mg ratio through magnesium supplementation may increase HDL-c in 
participants with long-term high Ca:Mg intake ratios. A meta-analysis of nine 
randomized trials conducted among type 2 diabetic patients, individuals at high risk of 
magnesium deficiency 312, showed that oral magnesium supplementation significantly, 
but weakly, increased HDL-c by 0.08 mmol/l, and had no effect on LDL-c and 
triglycerides 212. Our study is consistent with this meta-analysis and found a stronger 
effect of magnesium supplement when the Ca:Mg ratio is considered. These human 
findings are consistent with the evidence from animal studies indicating that calcium-
adequate and magnesium-deficient diets lead to increases in heart lipid peroxidation, 
plasma levels of triglycerides, as well as inflammatory markers; whereas both calcium-
deficient and magnesium-deficient diets normalize the levels of inflammatory markers, 
lipid peroxidation and plasma triglycerides concentration 52,53. 
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Both metabolic syndrome and deficits of calcium or magnesium are potential risk factors 
of colorectal neoplasia. However, no studies have examined whether the Ca:Mg ratio 
may have a role in uric acid metabolism nor whether uric acid is an intermediate 
between the association of the Ca:Mg ratio and colorectal neoplasia. Our findings 
indicated the Ca:Mg ratio may not affect risk of cancer or cardiovascular disease by 
modifying uric acid. Future studies should evaluate whether the Ca:Mg ratio may affect 
biomarkers such as lipid profiles 323 and uric acid. We also cannot exclude the 
possibility that the null result for uric acid in the current study is due to a small sample 
size so future larger studies may be needed. 
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